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Chapter I General introduction  
I.1 Introduction 
The first large-scale commercial implementation of freeze-drying in a pharmaceutical 
environment was accomplished with freeze-drying of human blood plasma during World 
War II.1,2 Since then, a lot of research into the biophysics of freezing and freeze-drying was 
made. However, the emergence of widely used recombinant protein pharmaceuticals put 
freeze-drying on the spot.3,4 This is particularly linked to the complexity in both the 
production and the limited physicochemical stability of proteins.4 Most of the typical 
protein-related degradation pathways like chemical reactions (e.g., hydrolysis) or physical 
mechanisms (e.g., aggregation) are generally slowed down in the solid state due to the 
reduction of molecular mobility and significant reduction of water content.5–8 The reader 
interested in aspects of protein stability in general 8–10 and protein stability in the solid state 
in particular 4,11–13 is referred to literature. 
In the following section, the process of freeze-drying will be described at a glance. 
I.2 The freeze-drying process  
Freeze-drying, synonymously called lyophilization, is a multistage operation which is the 
drying method of choice for protein pharmaceuticals until today. The classic conventional 
freeze-drying is performed in a batch-mode and is described as a time-consuming, highly 
energy consumptive, costly process raising additional challenges during drug product 
manufacturing.3,13,14 Generally, the lyophilization process comprises three process steps, (i) 
freezing, (ii) primary drying which is characterized by the removal of crystallized water by 
sublimation under vacuum with gentle heating and (iii) secondary drying in which unfrozen 
water is desorbed under vacuum by controlled heating to more elevated temperatures.13,15 
I.2.1 Freezing 
After filling of the liquid in the container and placing it on the shelves of the freeze-dryer, 
the temperature of the system is lowered until the solvent separates from the solute by 
crystallization.16,17 Searles et al.18 divided the freezing of water (which normally is the main 
component of pharmaceutical solutions to be freeze-dried) into four steps which comprised 
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(1) the cooling of the solution below its equilibrium freezing temperature, i.e. supercooling, 
(2) the formation of an ice nucleus, i.e. primary nucleation, (3) the instant subsequent growth 
of an ice nucleus to ice crystals, i.e. secondary nucleation, and (4) the final solidification by 
the completion of the liquid-to-solid phase transition by proceeding ice crystal growth. The 
supercooled solution is metastable and is, therefore, prone to spontaneous crystallization of 
ice. The higher the degree of supercooling the more the number of ice nuclei increases and 
thus the probability of ice crystallization.18–21 Besides, a higher degree of supercooling 
corresponds with the formation of smaller ice crystals which in turn directly affects the 
average pore size within the generated cake structure leading to a rather poor drying 
performance during the subsequent sublimation phase, but an improved desorption 
drying.4,18,22 However, pharmaceutical solutions normally represent multi-component 
systems which ultimately either leads to eutectic freezing or vitrification upon lowering the 
temperature. Eutectic freezing refers to the solute crystallization from a cryoconcentrated 
solution and is characterized by the eutectic melting temperature (Teu). The formation of a 
eutectic mixture can often be seen for excipients that are known to crystallize upon freezing, 
e.g. mannitol or glycine. In contrast, the vitrification occurs in systems with excipients that 
tend to form an amorphous solute phase, e.g. sugars or certain arginine salts 23 and is 
characterized by the glass transition temperature of the maximally freeze-concentrated 
solution (Tg’). This occurs in the case of phase separation of a crystalline ice phase and an 
amorphous solute phase leading to an increase in solute concentration by further 
crystallization of water. At the Tg’ the viscosity of the freeze-concentrate changes 
approximately four orders of magnitude over a small temperature range leading to a rigid 
glass system below Tg’.
17,22 Another characteristic parameter is the collapse temperature 
(Tc). Tc is the (total) loss of structure caused by viscous flow and, therefore, represents the 
maximum allowable product temperature that must not be exceeded during the subsequent 
drying procedure if the pharmaceutical elegant appearance and porous structure of the 
lyophilizate should be maintained.24,25 Generally, Tg’ measured by differential scanning 
calorimetry (DSC) represents an easy to access surrogate for Tc, which is normally 
determined by laborious and operator-dependent freeze-drying microscopy (FDM). For 
placebos or low protein concentration amorphous formulations (≤ 25 g/L), Pansare et al. 
suggest Tg’ ~ Tc.
26 In general, Tc is described to be 1 K to 5 K higher as Tg‘, but in certain 
systems like high protein concentration formulations, higher deviations are reported.25–29 
All in all, the freezing step may have a detrimental effect on the incorporated protein. 
Especially when keeping in mind that freezing is associated with several stresses like cold 
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denaturation 11,30–32, freeze- or cryoconcentration 7,22,33,34, pH shifts due to crystallization of 
buffer components 30,35 and protein interaction with ice indirectly 36 or via adsorption to the 
ice surface at the ice-liquid interface 37. 
The interested reader is referred to reviews by Kasper et al.17 and Assegehegn et al.38 for a 
sound overview of the freezing step in pharmaceutical lyophilization. 
I.2.1.1 Annealing 
One modification of the freezing step is the addition of a thermal treatment after 
solidification of the system called annealing. By raising the shelf temperature to a value 
above the Tg’ of the solute, the complete crystallization of crystalline compounds is 
promoted 22. Also, annealing is reported to decrease inter-vial heterogeneity and to improve 
primary drying rates.22,39,40 
I.2.1.2 Controlled ice nucleation 
Another modification is the control of the ice nucleation temperature (TN). Controlled ice 
nucleation (CN) as such refers to the control of TN of all vials and thus control of the degree 
of supercooling of the filled solution by introducing a stimulus to the supercooled solutions. 
Normally, the ice nucleation among the batch is a stochastic event, leading to a distribution 
of nucleation temperatures and, hence, to an inter-vial heterogeneity concerning pore size 
distribution and subsequent drying performance. Moreover, especially when transferring a 
process from laboratory scale to a production environment, shelf-ramped frozen samples 
tend to a higher degree of supercooling due to less airborne heterogeneous nucleation sites 
in a Class 100 environment.41 By the employment of controlled ice nucleation, these 
challenges during process transfer and scale-up could be overcome or at least diminished. 
Moreover, the lowering of the degree of supercooling by application of CN leads to the 
formation of larger ice crystals and thus larger pores which typically result in lower 
resistance to water vapor during the sublimation phase, but leading to a reduced specific 
surface area.42,43 
Several techniques for controlled ice nucleation are reported in the literature, some of them 
with commercial implementation. The most common techniques are based on (1) the 
introduction of ice seeds by ice fog 41,44–49, (2) the application of rapid pressure changes 
48,50,51, or (3) the application of vacuum to induce local surface freezing 52–54. Although the 
benefits and advantages of controlled ice nucleation from a process time 40,43,50,52,53,55, whole 
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batch, and/or product quality perspective 40,43,54–59 have been shown widely, shelf-ramp 
freezing is still the gold standard in most commercial processes.  
The interested reader is referred to a review by Geidobler et al.21 for more background on 
controlled ice nucleation. 
I.2.2 Primary drying 
The primary drying is the sublimation drying in which the frozen solvent, i.e.in most of the 
cases water, is removed from the product under vacuum. The basis for this is that the 
chamber pressure is kept well below the vapor pressure of ice at the target product 
temperature.39,60 As the phase transition from solid to gaseous consumes energy, the 
sublimation enthalpy needed is provided by the heated shelves to keep the sublimation 
ongoing. In conventional primary drying, the majority of ice is sublimed in a quasi-steady 
state which can be expressed as coupled heat and mass transfer and which needs to be 
balanced during primary drying.7 That means, it should be balanced in a way that the product 
temperature does not exceed the maximum allowable product temperature (e.g. Tc) but is 
kept as close as possible to it.61 This necessity becomes obvious when taking into account 
that an increase in product temperature by 1 °C is reported to decrease primary drying time 
by around 13 %.62 For a rational design of the primary drying step, the chamber pressure and 
the shelf temperature have to be defined. In the following, three important relations from 
Tang and Pikal 39 explaining the interaction of the variables concerning the heat and mass 
transfer will be discussed:  
(1) The dependence of the ice sublimation rate dm/dt of the chamber pressure Pc in vials 
is expressed by Equation I-1 (Pice equilibrium vapor pressure of ice at the sublimation 
interface temperature; Rp resistance of the dried-product layer above the frozen 
product): 
𝑑𝑚
𝑑𝑡
=  
𝑃𝑖𝑐𝑒−𝑃𝑐
𝑅𝑝+𝑅𝑠+𝑅𝑐
 (Equation I-1, modified from Tang and Pikal 39) 
 
The sublimation rate is proportional to the pressure difference. Consequently, the lower the 
chamber pressure, the higher the ice sublimation rate. However, due to technical challenges 
associated with very low chamber pressures 63 and reports on increased heterogeneity in heat 
transfer 60, Tang et al.39 recommend an operating space from 66 µbar to 266 µbar. In general, 
the dried-product layer Rp represents the main hindering factor to water vapor flow, 
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wherefore the resistance to of the semistoppered vial Rs and the resistance to transfer from 
drying chamber to the condenser Rc could be neglected. However, care must be taken as Rp 
increases with progressing drying.64  
(2) The general relation between heat transfer rate (dQ/dt) and mass transfer rate (dm/dt) 
is given by the expression: 
 
𝑑𝑄
𝑑𝑡
= ∆𝐻𝑠 ∗
𝑑𝑚
𝑑𝑡
 (Equation I-2, from Pikal et al.60) 
 
The heat transfer rate is directly proportional to the mass transfer rate via the heat of ice 
sublimation (ΔHs) as a proportional factor. 
(3) In vials, the heat transfer rate (dQ/dt) is defined as (Q energy received by each vial 
from the shelf; Av outer area of vial bottom; Kv vial heat transfer coefficient; Ts shelf 
temperature; Tb product temperature at the bottom center of the vial): 
 
𝑑𝑄
𝑑𝑡
= 𝐴𝑣 ∗ 𝐾𝑣 ∗ (𝑇𝑠 − 𝑇𝑏) (Equation I-3, from Pikal et al.60) 
 
Kv is the sum of the heat flow contributions from conduction (Kc), thermal radiation (Kr), 
and gas convection (Kg). The main heat transfer mechanisms in conventional freeze-drying 
are the conductive heat transfer Kc by direct conduction from shelf to vial at the points of 
contact and the convective heat transfer Kg which represents the conduction through the gas 
between shelf and vial bottom with the latter being proportionally related to the chamber 
pressure.60,65 The contribution of radiative heat transfer Kr is normally minor due to the low 
temperatures encountered in classical freeze-drying operations.66 However, the contribution 
of Kr has to be considered particularly when (1) emerging modified freeze-drying 
technologies like microwave-assisted freeze-drying (section I.3.2, Chapter II & Chapter III) 
are used or (2) in terms of altering edge vial effects during scale-up as investigated by 
Rambhatla et al 67. 
 
All in all, the time needed for completion of primary drying can be decreased by an 
optimized sublimation rate which can be enhanced by an increased product temperature. The 
latter being directly affected by both the pressure difference between the vapor pressure of 
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ice at the sublimation interface temperature and chamber pressure (Equation I-1) and the 
temperature difference between shelf temperature and product temperature (Equation I-3). 
However, dependencies between the variables, maximum allowable temperatures (e.g. Tc, 
Teu), and product-specific aspects (e.g. Rp) have to be taken into account. 
I.2.3 Secondary drying 
At the end of primary drying, the frozen water is removed by sublimation leaving only the 
unfrozen water in the solute phase. In amorphous products, 20 % to 30 % (w/w) residual 
water on a dried solids basis is still contained.68 The applied desorption drying during 
secondary drying should reduce the residual moisture content within the product in a way to 
ensure a sufficiently long shelf life, i.e. storage stability, at the desired storage temperature.69 
Usually, residual moisture levels < 1 % are aimed at.39 However, the optimal residual 
moisture content for long-term stability can vary for different proteins and formulations 70,71 
and even “over-drying” has been discussed 72–74. 
Due to the relatively high residual moisture content at the beginning of secondary drying 
and, thus, low glass transition temperature, the risk for collapse during the initial heat ramp 
is increased. To prevent the cake from (partial) collapsing, a rather slow temperature ramp 
should be applied. In general, the efficacy of secondary drying is a function of the shelf 
temperature and to a lesser extent of the duration and chamber pressure.75 Franks 68 suggests 
that the secondary drying is based on diffusion rather than desorption shown by the non-
linear drying kinetics seen for Ficoll glass films at different isothermal drying profiles. 
Hence, the achievable water content at a given temperature is rate limited leading to the 
general recommendation to run a high shelf temperature for a short time. 
Besides the shelf temperature, the residual moisture content is only dependent on the specific 
surface area which in turn is indirectly proportional to the pore size and, hence, can be 
directly proportional to the degree of supercooling.68 
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I.3 Emerging developments in the field of freeze-drying  
An exhaustive and comprehensive overview of all emerging developments related to freeze-
drying is out of the scope of this introduction. However, some selected innovations in the 
field of pharmaceutical freeze-drying that reached at least prototype status or represent an 
evolution in the author’s view should be highlighted in the following. 
I.3.1 Spray freeze-drying 
Spray freeze-drying (SFD) represents the combination of spray-drying and freeze-drying. 
The process comprises three stages which are (1) the atomization of a liquid to generate 
droplets, (2) the fast freezing of the generated droplets under cryogenic conditions and, (3) 
the removal of solvent from the frozen bulk pellets employing freeze-drying.13,76 The 
application of SFD may have several benefits over conventional freeze-drying (CFD) like 
the generation of a porous (sterile) bulk material, improved reconstitution behavior of the 
product, significantly reduced process times due to improved heat and mass transfer, 
potential flexibility in dosing and easy to achieve combination products (e.g. for protein co-
formulations with contradicting stability profiles or different antigens within one vaccine) 
by dosing of different bulk powders in one vial and the potential for a (semi)continuous 
process.13,76–79 However, potential downsides could be the generation of a high specific 
surface area of the bulk powder. The degradation rate in a solid state of human growth 
hormone was correlated to the protein quantity on the air-solid interface by Xu et al. 80. Other 
potential pitfalls could be related to the implementation in a GMP environment, to the 
challenging process design 77,78, additional space demand in height due to the length of the 
freezing tower, sufficiently free-flowing of the bulk powder, electrostatic charging and 
accurate filling of the pellets in the final primary container.  
I.3.2 Microwave-assisted freeze-drying  
Microwave-assisted freeze-drying (MFD) refers to the use of dielectric heating, i.e. the 
application of microwaves to the frozen good. Durance et al. 13 describe the process to 
comprise of freezing at ambient pressure, primary and secondary drying under vacuum; 
therefore, identical to the CFD at first glance. However, sublimation and desorption are 
mainly a result of the heat supplied by microwave power. Important to note is that 
microwaves as electromagnetic waves itself interact with the material, but do not inherently 
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possess heat to be transferred to the good. More detailed information on the physics of 
microwaves is given in Chapter II and Chapter III. The application of MFD may have several 
benefits over conventional freeze-drying like the significant reduction of drying time 81, 
lower operating costs due to decreased energy consumption, higher throughputs 13, 
volumetric heating of the entire sample 82, the potential for (semi)continuous processing. 
However, there are several challenges reported for MFD, e.g. larger heterogeneity due to 
non-uniformity of the electromagnetic field 81–85, selective heating of single formulation 
components 86, challenging equipment and process design for pharmaceutical applications 
and occurrence of arcing leading potentially to product loss 13,82. 
I.3.3 Continuous freeze-drying 
Bearing in mind that one major disadvantage of the conventional freeze-drying is the 
limitation to the batch mode, continuous freeze-drying could potentially be a huge evolution 
in the pharmaceutical manufacturing of solid dosage forms for parenteral administration.  
The general advantages of a continuous mode over the classic batch-mode comprise 
operation flexibility, reduced or no scale-up challenges, real-time quality assurance, 
reductions in footprint, investment, and operative costs.87 Pisano et al. 88 summarized in 
particular the advantages a continuous freeze-drying process could have, covering 
operational aspects (e.g. downtimes, batch-to-batch variability) and scale-up aspects (e.g. 
equipment change, differences in the process caused by equipment/environment).  
 
Two approaches that work with unit-doses shall be presented briefly:  
 
(1) The spin freezing and subsequent infrared drying concept was first described by 
Corver with a patent filing in 2012.89 Since then, several reports described the 
procedure in detail.90–94 The process comprises a continuous spin freezing creating a 
thin frozen product layer spread homogeneously over the inner vial surface followed 
by a subsequent continuous radiative drying by the employment of infrared radiation 
to the vial on a moving belt under vacuum. The main advantage of this approach is 
the continuous processing of unit doses in a rather short time as freezing and 
particularly drying are faster compared to CFD. Moreover, a 100% process control 
through process analytical tools like near-infrared spectroscopy is feasible. However, 
the development of mechanistic models to calculate maximum allowable energy 
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transfer to the frozen product layer and to enable prediction of process behavior is 
still needed.95 Moreover, the essentially new process and concomitant new 
appearance of the final dried drug product needs a change in thinking at drug product 
manufacturers, regulatory agencies, and health care professionals. 
(2) The suspended-vial configuration concept by Capozzi, Pisano, and Trout was first 
introduced in 2019 96. In contrast to the spin freezing approach by Corver et al., the 
suspended-vial configuration appears like a continuously thought conventional 
freeze-drying, meaning that continuation of the process should be achieved by the 
introduction of a track system along different separated (vacuum) chambers that are 
dedicated to a different operation. Nevertheless, the inclusion of a method to apply 
controlled ice nucleation (vacuum-induced surface freezing) during freezing as well 
as the employment of radiative heating rather than conductive/convective heating 
seems to be a promising approach for the future. However, until now, the concept is 
only of theoretical nature and based on preliminary data from a batch-mode with no 
proof of concept for the continuously operating plant.96 
 
The reader interested in more detailed information about continuous manufacturing in 
lyophilization is referred to the review by Pisano et al. 88. 
 
I.4 Aim and outline of the thesis 
Over the last years, serious interest in emerging next-generation freeze-drying technologies 
raised. One promising technology that stands out due to its proven benefits in food 
technology is microwave-assisted freeze-drying (MFD). As briefly outlined in section I.3.2, 
MFD has the potential to overcome drawbacks like long drying-times due to its volumetric 
heating of the entire sample.  
However, little is known of its feasibility for pharmaceutical applications, particularly in the 
field of sensitive biologicals. For this reason, the first part of this thesis, Chapter II and 
Chapter III, is dealing with the investigation of vial-based microwave-assisted freeze-
drying concerning the applicability to standard lyophilization formulations and effects on 
protein stability.  
In Chapter II, the applicability and feasibility of this technology to different monoclonal 
antibody formulations and the influence on the resulting product properties are subject to 
investigation. Moreover, the potential for drying time savings is examined.  
Chapter I 
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The product quality of four different pharmaceutically relevant monoclonal antibody 
formulations over storage and the influence of the microwave generator on batch 
homogeneity are studied in Chapter III.  
The second part of this work, Chapter IV – Chapter VI, is dedicated to detailed 
investigations on open questions in controlled ice nucleation (CN) in the field of freeze-
drying of biologicals. Although there have been multiple publications, reports and case 
studies about CN over the last two decades, experts in the freeze-drying community are still 
lacking essential information on aspects of comparability of different controlled ice 
nucleation techniques, general good practice of process design and how to monitor the 
nucleation success of a whole batch non-destructively.  
In Chapter IV, a case study of three relevant model formulations is presented which aims 
to investigate if mechanistically different controlled ice nucleation techniques in freeze-
drying are comparable to each other concerning drying process performance and product 
quality attributes. 
A study analyzing factors that affect the success of CN and questions of process design are 
studied and discussed in Chapter V. 
In Chapter VI a new technological solution for control of the nucleation success using a 
camera-based approach is presented in a proof of concept study.  
Chapter VII summarizes and concludes the results of the present thesis and gives an 
outlook. 
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II.1 Abstract 
Microwave-assisted freeze-drying is a rapid drying process well-known in food technology. 
However, little is known about its application to biologicals. In this study, we investigated 
the applicability and feasibility of this technology to different monoclonal antibody 
formulations and the influence on the resulting product properties. Moreover, one of our 
main objectives was to study if significant reductions in drying times could be achieved. 
Additionally, the effect of the drying process on the accelerated stability of a sucrose-based 
antibody formulation at 40 °C and 25 °C over 12 weeks was investigated. Microwave-
assisted freeze-drying resulted in drying time reduction > 75 %. For all model formulations, 
cake appearance and solid state properties were found to be comparable to standard 
lyophilized products. These formulations covered a wider range of lyophilization excipients 
comprising sucrose and trehalose, semi-crystalline forming solids like mannitol:sucrose-
mixtures and others like arginine phosphate and a mixture of HP-β-CD with sucrose. 
Moreover, comparable low changes in relative monomer content, the relative amount of 
soluble aggregates, and cumulative particles ≥ 1µm per mL were observed over 12 weeks of 
storage, regardless of the drying technology. This makes MFD a promising innovative 
alternative for the rapid production of freeze-dried biologicals while maintaining product 
quality. 
 
Keywords 
Freeze-drying/lyophilization; Lyophilization; Drying; Proteins; Stability; Excipients; Solid 
state; Monoclonal antibody; Glass 
Abbreviations 
API  Active pharmaceutical ingredient  
BET  Brunauer–Emmet–Teller Krypton gas adsorption 
CFD  Conventional freeze-drying 
HMW  High molecular weight species 
HPW  Highly purified water 
HP-β-CD 2-Hydroxypropyl-β-cyclodextrin 
LMW  Low molecular weight species 
mAb  Monoclonal antibody 
MFD  Microwave-assisted freeze-drying 
MW  Microwave 
MWCO  Molecular weight cut-off 
PES  Polyethersulfone 
rM  Residual moisture content 
SEC  Size exclusion chromatography 
SSA  Specific Surface Area 
XRD  X-ray diffraction 
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II.2 Introduction 
Long process times are a typical shortcoming of conventional freeze-drying (CFD).97,98 One 
approach to reduce drying time is microwave-assisted freeze-drying (MFD) which is a well-
known process in food technology for high-value goods needing significantly shorter process 
times while maintaining the overall quality of the product, i.e. color, taste, texture, shape.99–
101 Especially in the field of food processing, microwave radiation has versatile applications 
like cooking, drying, or preservation of food products.84 Due to its ability to allow for a rapid 
heat transfer and because of the volumetric and selective heating of dielectric material, it has 
major advantages over other conventional drying techniques. In contrast to heating via 
convection or conduction, microwaves as electromagnetic waves directly interact with 
dielectric materials such as permanent dipoles, e.g. water or disaccharides, or ions, e.g. 
buffer salts.82 In particular, drying at the typical industrial frequency of 2.45 GHz is mainly 
driven by the interaction of permanent dipoles and microwaves.102 The capability of a 
material to absorb microwaves and thereby to convert electric field energy into thermal 
energy by molecular interactions with the electromagnetic field is characterized by the 
frequency-depending absolute complex permittivity.103 More detailed information on the 
physical principles of microwave heating can be found elsewhere 82,84,103,104. As typical 
lyophilization formulations used for biologicals are based on aqueous systems containing 
polar stabilizers, e.g. sucrose or trehalose, buffer salts, and the API, 7 suitability for a 
microwave-assisted drying process is likely. Therefore, MFD also raised interest in 
pharmaceutical applications recently. As reported by Robert Evans at the CPPR conference 
in 2014, microwave-assisted drying could be applied to both monoclonal antibody and 
vaccine formulations.105 In preliminary data, they found similar aggregation rates as obtained 
by HP-SEC for two monoclonal antibodies and no severe loss in antigen potency for 
different vaccine formulations. Based on that an international patent is pending, claiming the 
formulation and production of thermostable dried vaccine formulations using microwave 
vacuum drying.106 The inventors claim for shortened drying processes by MFD. However, 
high sugar concentrations of 17.5 % (w/w) up to 60 % (w/w) in combination with vaccines 
were investigated. Therefore, our aim is to have a closer look at the applicability of MFD to 
various pharmaceutically relevant formulations of a monoclonal antibody with a different 
experimental setup. In this article, we show the successful implementation of MFD for 
excipient concentrations of 10% (w/v) or 1% (w/v). Additionally, the main focus will be on 
maintenance of product quality while shortening the drying time significantly. Moreover, 
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we study the accelerated stability of a sucrose-based IgG antibody formulation over three 
months either produced by CFD or MFD. 
II.3 Materials and methods 
II.3.1 Materials 
A monoclonal IgG type 1 antibody (mAb) was kindly provided by Boehringer Ingelheim 
Pharma GmbH & Co. KG (Ingelheim am Rhein, Germany). 
D(+)-Sucrose and L-Arginine were purchased from Sigma-Aldrich (Steinheim, Germany). 
D(+)-Trehalose dihydrate and D(-)-Mannitol were obtained from VWR International BVBA 
(Leuven, Belgium). 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) (Cavasol® W7 HP, 
Wacker Chemie AG, Burghausen, Germany) was a kind gift of PARI GmbH (Starnberg, 
Germany). L-Histidine monohydrochloride monohydrate and L-Histidine were purchased 
from Alfa Aesar (Karlsruhe, Germany). Di-sodium hydrogen phosphate dihydrate and 
sodium dihydrogen phosphate dihydrate were obtained from AppliChem (Darmstadt, 
Germany). Sodium chloride was purchased from Bernd Kraft (Duisburg, Germany). Tween 
80®, ortho-Phosphoric acid, and sodium hydroxide were obtained from Merck KGaA 
(Darmstadt, Germany). For the preparation of buffers and stock solutions, highly purified 
water (HPW; Purelab Plus, USF Elga, Germany) was used. 
All excipients had at least analytical grade and were used without further purification. 
II.3.2 Preparation of formulations 
The mAb was concentrated prior to dialysis by using Vivaspin 20 with PES membrane 
(MWCO 30,000 Da; Sartorius AG, Goettingen, Germany) and then subsequently dialyzed 
for 24h using dialysis membranes Spectra/Por® (MWCO 6000 – 8000 Da; Spectrum 
Laboratories Inc., Compton, CA, USA). After the dialysis concentration of mAb was 
measured with a NanoDrop™ 2000 UV photometer (Thermo Scientific, Wilmington, 
Delaware) at 280 nm using an extinction coefficient of ε0.1% = 1.49 g/100 mL−1 cm−1. For the 
preparation of the final formulations, excipient stock solutions ranging from 1 % to 25 % 
(w/v) prepared in 10 mM Histidine buffer (pH 6.0) were mixed with the dialyzed mAb 
solution in 10 mM Histidine buffer (pH 6.0) in a way that final formulations contained either 
3 or 5 g/L mAb, 0.02 % (w/v) tween 80® and either 10 % (w/v) sucrose or trehalose or HP-
β-CD:sucrose 1:1 or mannitol:sucrose 4:1. For the low stabilizer containing formulation the 
same procedure was applied but ending up with a lower final sucrose concentration of 1% 
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(w/v), 3 g/L mAb, and 0.02 % (w/v) tween 80®. The arginine phosphate formulation 
contained 10 % (w/v) of arginine phosphate to which 5 g/L of mAb dialyzed in 10 mM 
arginine phosphate (pH 6.0) and 0.02 % (w/v) tween 80® prepared in 10 mM arginine 
phosphate (pH 6.0) were added. A tabular overview of the used formulations could be found 
in the supplementary data (Table SII-1). The formulation for the accelerated stability study 
contained 5 g/L mAb and 10 % (w/v) sucrose as mentioned above. All formulations were 
filtered using 0.2 µm Cellulose Acetate Membrane syringe filters (VWR International, 
Radnor, PA, USA) prior to filling of the vials. 2.3 mL of each formulation was filled in 10R 
tubing vials (MGlas AG, Muennerstadt, Germany) and semi-stoppered with lyophilization 
stoppers (FluroTec® rubber stopper, West Pharmaceuticals, Eschweiler, Germany). The vial 
population for conventional freeze-drying was arranged on a lyophilization tray and 
surrounded with one row of 10 % (w/v) sucrose shielding vials. 
II.3.3 Freeze-drying process 
All samples were frozen in the same freezing step using a Christ ε2-6D laboratory-scale 
freeze-dryer (Martin Christ, Osterode am Harz, Germany) with equilibration at -5 °C for 1 
h followed by ramping down the shelf with 1 K/min to -60 °C set point. The frozen samples 
were subjected to one of the following drying protocols: 
II.3.3.1 Conventional freeze-drying (CFD) 
Primary Drying was carried out at a pressure of 0.1 mbar and a shelf temperature of -20 °C. 
T-type thermocouples were used to determine primary drying time. Secondary drying was 
carried out at 0.05 mbar applying a 0.05 K/min ramp to 0 °C and subsequently, a ramp of 
0.2 K/min to 20 °C which was held for 6h. After completion of the drying, samples were 
stoppered at approximately 600 mbar in a nitrogen atmosphere and kept refrigerated until 
analysis. 
II.3.3.2 Microwave-assisted freeze-drying (MFD) 
Drying was conducted on a modified laboratory-scale Püschner µWaveVac 0250fd vacuum 
dryer (Püschner GmbH + Co KG, Schwanewede, Germany) 107,108 equipped with a 
2 kW/2450 MHz magnetron, a condenser (-80 °C) and a vacuum system comprising a root 
pump and a rotary vane pump. The tuner, which was located between the magnetron and 
water load, was adjusted that way that approximately 1/10 of the generated microwaves went 
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into the product chamber. Frozen samples, which were frozen as described above and which 
were transported on dry ice, were loaded on the pre-cooled rotating sample tray. Drying was 
carried out at a pressure of 0.008 to 0.03 mbar as measured by Pirani gauge and at a radiated 
microwave power between 20 W to 110 W as measured by a HOMER™ impedance analyzer 
(S-TEAM Lab, Bratislava, Slovak Republic) until a constant mass was reached. For process 
monitoring a glass fiber temperature measurement probe (TS2, Weidmann Technologies 
Deutschland GmbH, Dresden, Germany) and a balance to determine total weight loss were 
used. Samples were stoppered externally in a glove bag flushed with dry nitrogen and kept 
refrigerated until analysis. 
II.3.4 Residual moisture content 
Karl Fischer titration was used to determine residual water content after freeze-drying. 
Between 10 and 30 mg of sample aliquots were prepared in a glove box filled with 
pressurized air with a relative humidity of less than 10%, filled into 2R Vials and stoppered. 
The samples were then placed in an oven with 100 °C to enable the fast extraction of water. 
The headspace moisture is transported into a coulometric Karl Fischer titrator (Aqua 40.00, 
Elektrochemie Halle, Halle (Saale), Germany). Results are calculated in relative water 
content (w/w). 
II.3.5 Specific surface area 
The specific surface area of dried samples was determined using Brunauer–Emmet–Teller 
(BET) krypton gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1; 
Quantachrome, Odelzhausen, Germany). Approximately 80 – 140 mg of a sample was gently 
crushed with a spatula and weighed into glass tubes. Prior to measurement, an outgassing 
step was performed for at least 6 h at room temperature. A 9-point gas adsorption curve was 
measured, covering a p/p0 ratio of approximately 0.05– 0.25. Data evaluation was performed 
according to the multipoint BET method fit of the Autosorb 1 software. 
II.3.6 X-ray powder diffraction 
To determine the solid state of the lyophilizates an XRD 3000 TT diffractometer (Seifert, 
Ahrensburg, Germany) was used. The device is equipped with a copper anode (40 kV, 30 
mA) and has a wavelength of 0.154178 nm. The scintillation detector voltage was 1000 V. 
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The samples were placed on the copper sample holder and analyzed in the range of 5-45 ° 
2-theta with steps of 0.05° 2-theta. 
II.3.7 Reconstitution of lyophilizates 
The lyophilized cakes were reconstituted by the addition of HPW. The HPW volume for 
each formulation was calculated to match the volume of the water removed during freeze-
drying.  
II.3.8 High-performance size exclusion chromatography (HP-SEC) 
To determine relative monomer content and the relative amount of soluble aggregates HP-
SEC was used. The separation was performed on a Waters 2695 Separation module (Waters 
GmbH, Eschborn, Germany) with a Tosoh TSKgel G3000 SWxl column (Tosoh Bioscience, 
Griesheim, Germany) using a Waters 2487 Dual λ Absorbance Detector (Waters GmbH, 
Eschborn, Germany) at 214 and 280 nm. 10 µL of reconstituted formulation with a final 
concentration of either 3 or 5 g/L was injected and separated using a 50 mM PBS running 
buffer containing 300 mM sodium chloride (pH 7.0) with a flow rate of 0.7 mL/min. Samples 
were measured as triplicates with three individual injections. Data integration of relative 
areas was performed using Chromeleon 6.80 (Thermo Scientific, Wilmington, USA).  
II.3.9 Light Obscuration 
Subvisible particles were determined using a PAMAS SVSS-35 particle counter (PAMAS - 
Partikelmess- und Analysesysteme GmbH, Rutesheim, Germany) equipped with an HCB-
LD- 25/25 sensor which has a detection limit of approximately 120,000 particles ≥ 1 µm per 
mL. The rinsing volume was 0.5 mL and was followed by three measurements of 0.3 mL. 
Before and between samples the system was rinsed with HPW until less than 30 particles/mL 
 1 µm and no particles larger than 10 µm were present. Data collection was done using 
PAMAS PMA software and particle diameters in the range of ≥ 1 µm to 200 µm were 
determined. All results are given in cumulative particles per milliliter. 
II.3.10 Turbidity 
The turbidity of samples was measured as scattered laser light (λ = 860 nm) detected at an 
angle of 90 ° using a Hach Lange Nephla nephelometer (Hach Lange GmbH, Düsseldorf, 
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Germany). 2.0 mL sample was gently pipetted in turbidity glass cuvettes free of particles 
with a flat bottom and placed into the device. The result is given in FNU (Formazine 
nephelometric units). 
II.4 Results and discussion 
II.4.1 Applicability to different formulations 
II.4.1.1 Cake appearance 
With both microwave-assisted and conventional freeze-drying elegant and look-alike cakes 
could be produced (Figure II-1). Only for the low concentration stabilizer formulation with 
1% (w/v) sucrose (Figure II-1, b) and the ionic arginine phosphate-formulation (Figure 
II-1, f) shrinkage of the cake was observable in both processes.  
 
 
Figure II-1 Representative photographs of differently dried formulations. Small letters represent the 
excipient used: a 10% sucrose, b 1% sucrose, c 10% trehalose, d 10% mannitol:sucrose 4:1, e 10% HP-β-
CD:sucrose 1:1, f arginine phosphate. Top picture: CFD-products; Bottom picture: MFD-samples. The 
asterisk indicates that these formulations contained 5 g/L mAb and were dried in a separate but similar run to 
the one shown in Figure II-2. 
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II.4.1.2 Process time reduction  
Microwave-assisted freeze-drying resulted in a significantly shorter drying process as shown 
in Figure II-2. The conventional process (Figure II-2, A) was finished after approximately 
77h. Since primary drying was kept longer to allow for complete sublimation in all 
investigated formulations, the actual drying time in CFD could, therefore, be reduced by 
about 18h. Additionally, the 16h for the freezing step should be kept out of consideration 
since both CFD and MFD samples underwent the same freezing procedure. Consequently, 
the adjusted total drying time, i.e. primary and secondary drying time, for the conventional 
drying is estimated to be approximately 43h (Figure II-2, A curly brackets b+c). In contrast, 
the drying procedure using MFD (Figure II-2, B) yielded in a total drying time of nearly 10h, 
which is a reduction of 77 % in overall drying time. Even though a standardized non-
optimized conventional freeze-drying cycle was used, still differences in a large order of 
magnitude were achieved for the process time reduction using microwave-assisted freeze-
drying. 
 
Figure II-2 A Thermocouple and pressure readouts of the conventional freeze-drying cycle. Shelf temperature 
setpoint is represented by the dotted line, thermocouple readout is depicted with a solid line. The coarse dotted 
line represents the chamber pressure setpoint. Curly bracket a tags the freezing step which is the same for both 
batches, whereas curly brackets b and c represent the actual drying time of primary and secondary drying. B 
Glass fiber (solid line), chamber pressure (dash dot-line), microwave power (dotted line), and balance readings 
(dashed line) of the MFD-cycle. Product temperature measurement was performed in either case in the 10 % 
sucrose formulation. 
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II.4.1.3 Residual moisture and specific surface area 
For both drying technologies, low residual moisture content was found independent of the 
excipient system (Figure II-3, A, bars). Only the arginine phosphate formulation showed 
higher residual moisture of 2.3 % (w/w) after MFD. This could be related to the smaller 
specific surface area which indicates a micro-collapse compared to the conventionally dried 
product (Figure II-3, A, symbols). Overall, MFD products exhibited low residual moisture 
contents while the lyophilization-specific porous cake structure represented by the specific 
surface area was maintained. For some of the MFD samples, a higher variance could be 
determined, especially in the low concentration sucrose formulation, the 10 % trehalose, and 
arginine phosphate formulation. This was also observable in a 100 % analysis for solid state 
properties of a full batch of a sucrose-based formulation produced by MFD (Supplementary 
Data, Figure SII-1). It is assumed that this is on the one hand caused by the indirect setup of 
the magnetron to the product chamber via a water load which could favor an inhomogeneous 
field distribution. On the other hand, the sample handling in the used MFD laboratory setup 
was not yet optimal. This is due to the fact, that the first samples were frozen externally and 
kept deep-frozen until processing and second that dried samples were stoppered externally 
in a dry nitrogen-flushed glove bag.  
 
Figure II-3 A Residual moisture content (bars) and specific surface area (symbols) for all six formulations and 
the two respective drying protocols (black: conventional freeze-drying; light grey/white triangles: microwave-
assisted freeze-drying). B X-ray diffractograms of exemplary formulations. Abbreviations stand for: Suc – 10 
% sucrose, Man:Suc – 10 % mannitol:sucrose 4:1-mixture, HP-b-CD:Suc – 10 % HP-β-CD:sucrose 1:1-
mixture, ArgPho – 10 % arginine phosphate. 1 represents δ-Mannitol peaks at 9.7° and 20.4°; 2 indicates the 
overlapping peak of mannitol hemihydrate at 9.6°. Characteristic 2-theta values have been taken from the 
literature 109. The asterisk indicates that these formulations contained 5 g/L mAb and were dried in a separate 
but similar run to the one shown in Figure II-2. The shown values represent the mean of measurements from 
three different vials. Error bars indicate the standard deviation of the mean. 
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II.4.1.4 XRD 
Regardless of the drying approach, the same solid state was found for all formulations as 
determined by XRD (Figure II-3, B) and confirmed by DSC (Supplementary Data, Figure 
SII-2). Only mannitol:sucrose 4:1 formulations showed a semi-crystalline structure 
indicating mainly the formation of δ-Mannitol by characteristic peaks at 9.7°, 20.4°, and 
24.6° (Figure II-3, B, arrow 1). A detailed comparison of XRD diffractograms for this 
formulation is shown in the supplementary data (Figure SII-3). Indications for the formation 
of mannitol hemihydrate (Figure II-3, B, arrow 2) were found. The crystal modification of 
mannitol hemihydrate is unfavored due to its destabilizing effect on the dried product.109,110 
However, it was found to be present in conventionally and microwave-assisted FD samples. 
The application of a thermal treatment will be taken into consideration to crystallize mannitol 
in its favored anhydrous crystalline modifications. All other formulations, independent of 
the drying approach were found to be fully amorphous. 
II.4.2 Accelerated stability study 
In order to see the influence of the respective drying method on protein stability, a 10% 
sucrose formulation with 5 g/L mAb produced either by CFD or MFD was stored at 25 °C 
and 40 °C for 12 weeks. The drying processes which were adjusted to the formulation took 
41h 5min and 10h 15min for CFD and MFD, respectively. Although the microwave-assisted 
drying procedure decreased drying times by 75 %, residual moisture contents after freeze-
drying were determined to be similar as 1.1 ± 0.13 % for CFD and 1.0 ± 0.5 % for MFD 
samples. Over 12 weeks of storage no changes in solid state properties as specific surface 
area, residual moisture content, glass transition temperature, and solid state were observable 
(data not shown). Concerning relative monomer content (Figure II-4, A) and the relative 
amount of soluble species (Figure II-4, B, C) no changes were observed over 12 weeks of 
storage for both CFD and MFD even at 40 °C. This is confirmed by cumulative subvisible 
particle counts (Figure II-4, D symbols) and turbidity (Figure II-4, D bars) which show no 
clear trend and stay at comparably low levels over storage time.  
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Figure II-4 A Relative monomer content of a sucrose-based mAb formulation stored for 12 weeks as 
determined by HP-SEC; B and C represent the soluble high molecular weight and low molecular weight 
species, respectively. D Development of cumulative particles ≥ 1 µm/mL (symbols) and turbidity (bars) over 
12 weeks. The shown values represent the mean of measurements from 3 different vials. Error bars indicate 
the standard deviation of the mean. 
II.5 Conclusion and outlook  
With this study, we can confirm that microwave-assisted freeze-drying is able to shorten the 
freeze-drying process by more than 75 %. Moreover, it is applicable to various relevant 
antibody formulations while obtaining elegant look-alike cakes and similar solid state 
properties. The ionic stabilizer system arginine phosphate showed a higher variance in solid 
state properties and therefore needs to be studied further. Yet, our results show that after 12 
weeks of accelerated stability study no differences between conventionally and microwave-
assisted freeze-dried products were observable. Neither in solid state properties nor protein-
related properties like soluble aggregates and subvisible particles differences occurred for a 
sucrose-based antibody formulation at two different accelerated storage temperatures. It 
should be noted, that alternative setups are currently under development since MFD 
processes are more difficult to control compared to conventional freeze-drying processes. 
Additionally, typical challenges related to the application of microwaves in freeze-drying 
 
 23 
processes should be taken into account like the potential emergence of cold plasma and the 
potential induction of batch inhomogeneity due to cold and hot spots.  
However, microwave-assisted freeze-drying has the potential to become a highly promising 
alternative to the conventional approach. We were able to confirm its potential to 
significantly shorten drying times while maintaining product quality, which would be also 
the main requirement for continuous processing. This, in fact, makes MFD a promising 
concept for continuous pharmaceutical freeze-drying in the future. 
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II.6 Supplementary material 
II.6.1 Materials and methods 
II.6.1.1 Modulated dynamic scanning calorimetry (Glass transition 
temperature) 
The glass transition temperature of the lyophilizates was measured using a Mettler Toledo 
DSC 821e (Gießen, Germany) dynamic scanning calorimeter. Aliquots of 2 to 15 mg of 
dried lyophilized cake were compacted in an aluminum crucible and crimped in a glove box 
filled with pressurized air with a relative humidity of less than 10 %. A modulated DSC 
method heating from either 25 °C to 100 °C for sucrose or from 25 °C to 180 °C for all other 
formulations with a heating rate of 2 K/min, an amplitude of 1 °C and a period of 2 min was 
used in order to differentiate between reversed and non-reversed transitions. The glass 
transition temperature was evaluated from the reversed curve after a 100 point-smoothing 
operation as the inflection point of the glass transition using the Mettler StarE Software. 
II.6.1.2 Preparation of formulations 
Table SII-1 Overview of the different investigated formulations. 
Formula-
tion 
mAb 
[g/L] 
Sucrose 
[% (w/v)] 
Trehalose 
[% (w/v)] 
Mannitol 
[% (w/v)] 
HP-β-CD 
[% (w/v)] 
Arginine 
phosphate 
[% (w/v)] 
PS 80 
[% (w/v)] 
10 % Suc 3 10 - - - - 0.02 
1 % Suc 3 1 - - - - 0.02 
10 % 
Tre* 
5 - 10 - - - 0.02 
10 % 
Man:Suc 
3 2 - 8 - - 0.02 
10 % 
HP-β-CD
:Suc 
3 5 - - 5 - 0.02 
10 % 
Arg-Pho* 
5 - - - - 10 0.02 
10 % Suc  
Stability 
Study 
5 10 - - - - 0.02 
All stock solutions used were prepared in 10 mM histidine buffer (pH 6.0) despite the arginine phosphate 
formulation. For this, all stock formulations were prepared in 10 mM arginine phosphate (pH 6.0). The same 
is valid for the respective mAb stock solution which was either dialyzed in the respective histidine or arginine 
phosphate solution at pH 6.0. 
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II.6.2 Results 
II.6.2.1 Full Batch Homogeneity 
One hundred percent of a sucrose-based formulation with 3 g/L mAb dried by MFD was 
analyzed for its solid state properties in order to assess batch homogeneity. For all vials, low 
residual moisture content could be achieved, although a higher scattering of individual 
values was found (Figure SII-1, A). One reason may be the wider range of specific surface 
areas observed (Figure SII-1, B). Another reason could be a potential inhomogeneous 
microwave field distribution with the setup used which may cause hot and cold spots during 
the drying procedure. 
 
 
Figure SII-1 A Grouped distribution of residual moisture content of a full batch of a sucrose-based formulation 
with 3 g/L mAb as described in materials and methods produced by MFD, fitted to Gaussian distribution. 
B Grouped distribution of the specific surface area of the same batch as in A with a Gaussian fit. The drying 
process was similar to the one shown in Figure II-2. 
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II.6.2.2 DSC and solid state 
DSC analysis confirmed the results obtained by XRD. In Figure SII-2, example thermograms 
of formulations containing either sucrose or trehalose or arginine phosphate which were 
produced by MFD are shown. No indication for crystalline proportions was found.  
 
Figure SII-2 Example DSC thermograms that are complementary to Figure II-3B showing the reversed 
curves of microwave-assisted freeze-dried sucrose (Suc), trehalose* (Tre), and arginine phosphate* (ArgPho) 
formulations. The asterisk indicates that these formulations contained 5 g/L mAb and were dried in a separate 
but similar run to the one shown in Figure II-2. 
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Figure SII-3 X-ray diffractograms of semi-crystalline mannitol:sucrose formulations for the respective 
drying protocol with characteristic peaks for δ-mannitol (blue) or mannitol hemihydrate (red) at 9.7°, 20.4°, 
and 24.6° or 9.6° and 18.0° 2-Theta, respectively. 
. 
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III.1 Abstract 
In order to overcome the downside of long conventional freeze-drying (CFD) process times 
for monoclonal antibody formulations, microwave-assisted freeze-drying (MFD) was 
introduced. Recently, the general applicability and potential shortening of drying times were 
shown. However, little is known about the storage stability of MFD products compared to 
CFD references. Additionally, batch homogeneity issues were seen within MFD in the past. 
In this study, we examined four different formulations of two different monoclonal 
antibodies using three different glass-forming excipients: sucrose, trehalose, and arginine 
phosphate. These formulations were freeze-dried with two different drying protocols (CFD 
and MFD), stored for 24 weeks, and analyzed for solid-state and protein-related quality 
attributes. Moreover, a new microwave generator setup was investigated for its potential to 
improve batch homogeneity. In all investigated formulations, comparable stability profiles 
were found, although the classical magnetron generator led to inferior batch homogeneity 
with respect to residual moisture distribution. In contrast, the new MFD setup indicated the 
potential to approximate batch homogeneity to the level of CFD. However, for future 
applications, there is an unabated need for new machine designs to comply with 
pharmaceutical manufacturing requirements.  
 
Keywords 
freeze-drying; lyophilization; drying; microwave; protein; monoclonal antibody; stability 
 
Abbreviations 
τβ  Relaxation time (global mobility) 
BET  Brunauer–Emmet–Teller Krypton gas adsorption 
CEX  Weak cation exchange chromatography 
CFD  Conventional freeze-drying 
ESD  Equivalent spherical diameter 
FD  Freeze-drying/Freeze-dryer 
FT-IR  Fourier-transform infrared spectroscopy  
HMW  High molecular weight species 
HP  High performance 
LC-MS  Liquid chromatography coupled with mass spectrometry 
LO  Light obscuration 
mAb  Monoclonal antibody 
MFD  Microwave-assisted freeze-drying 
MW  Microwave 
MW Power Microwave power input 
MWCO  Molecular weight cut-off 
pChamber  Chamber pressure setpoint 
PES  Polyethersulfone 
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PS80  Polysorbate 80 
RM  Residual moisture content 
SEC  Size exclusion chromatography 
SSA  Specific Surface Area 
SvP  Subvisible particles 
Tc  Product temperature  
TShelf  Shelf temperature setpoint 
WFI  Water for injection  
XRD  X-ray diffraction 
III.2 Introduction 
Conventional freeze-drying (CFD), also referred to as lyophilization, is a gentle drying 
method to improve the long-term stability of pharmaceuticals, specifically of protein drugs.69 
The method is used for pharmaceutical industrial purposes since World War II for the 
preparation of human blood plasma 7 and the demand for freeze-drying remains high. By 
2018, one-third of all parenteral protein formulations approved by the European Medicines 
Agency were freeze-dried products.111 During lyophilization, the protein drug is 
immobilized in the solid state, by that slowing down chemical and physical degradation 
reactions.5–8,112 Additionally, freeze-dried solids may have other benefits with respect to 
shipping and storage.39  
In general, freeze-drying comprises three steps: freezing, primary drying (= sublimation 
drying), and secondary drying (= desorption drying). Typically, the sublimation step is 
widely described to be the most time-consuming, and conventional freeze-drying is 
associated with lengthy process times.7,27,48,113,114 One alternative drying method utilizing 
microwaves is known from the food industry: microwave-assisted freeze-drying.115 Here, it 
is specifically used for high-value goods like dry fruits.116 Similar to the conventional freeze-
drying process, the material to be dried first needs to be frozen. In a second step, the drying 
itself takes place. In contrast to CFD, the main heat transfer mechanism is radiation rather 
than convection and conduction. Especially polar substances, e.g. water, sugars, amino acids 
show good absorption of electromagnetic waves of wavelengths of 12.2 cm and frequencies 
of 2.45 GHz.82,104 In brief, the heating mechanism in pharmaceutics occurs due to dipolar 
and ionic mechanisms. When such a polar good is placed in an oscillating field, dipoles or 
ions try to realign in the direction of the electric field. Due to the ultra-rapid change in the 
direction of the electric field internal friction of the molecules is caused leading to heating 
within the material, i.e. volumetric heating. In the case of ions, a charge-driven migration is 
discussed.82,84,117 MFD has clear advantages over conventional drying processes, like 
significantly shorter process times 81,118 and in the field of food processing, maintenance of 
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shape, color, taste, odor, and texture 99–101,116. In the transition area between food and 
pharmaceutical technology, MFD was used for the gentle drying of bacteria suspensions. 
Ambros et al. 118 investigated the survival rate and viability of different bacteria cultures. 
They found comparable survival rates of the investigated cultures produced by MFD 
compared to conventional freeze-drying but were able to shorten process times by up to 80%. 
The first usage in pharmaceutical freeze-drying was presented by Evans et al. 105 at the CPPR 
conference in 2014 showing the general applicability to monoclonal antibody and vaccine 
formulations. On this basis, a handful of international patents were filed claiming 
engineering- 119 or formulation/process-focused 106,120 intellectual property. In a previously 
published work from our group 81 the general applicability to various pharmaceutical freeze-
drying excipient systems containing a monoclonal antibody was underlined. Moreover, the 
potential for process drying time reductions was discussed. However, two major questions 
have been raised and have not been answered yet: (1) how do different microwave-assisted 
freeze-dried antibody formulations perform in accelerated stability studies with respect to 
solid state and protein stability compared to a conventionally freeze-dried reference? (2) Is 
the inferior batch homogeneity found for MFD samples a general issue associated with 
microwave drying or are there ways to improve it? 
The current study examines four different formulations of two different monoclonal 
antibodies in the presence of three different glass-forming excipients: sucrose, trehalose, and 
arginine phosphate. These formulations were freeze-dried with two different drying 
protocols, i.e. using conventional freeze-drying and microwave-assisted freeze-drying. 
Moreover, a new microwave setup equipped with a semiconductor solid-state microwave 
generator was used for one of the formulations. Samples were stored for 24 weeks at different 
temperatures (2 - 8°C and 40°C) and analyzed at fixed times for their solid state and protein-
related quality attributes. We hypothesize that on the one hand irrespective of the 
monoclonal antibody formulation comparable stability profiles can be found for CFD and 
MFD. On the other hand, we anticipate the new microwave machinery set up to have a 
positive effect on batch homogeneity in microwave-assisted freeze-dried products.  
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III.3 Materials and methods  
III.3.1 Materials 
Two different IgG type 1 monoclonal antibodies (mAb) were investigated. mAb1 was kindly 
provided by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, 
Germany). mAb2 was an on stock at Ludwig-Maximilians-Universität München (LMU). 
For mAb1-formulations, the following excipients were used: ACS certified D(+) Sucrose, 
which was purchased from Sigma-Aldrich (Steinheim, Germany), D(+) Trehalose dihydrate 
(min. 99% purity) was obtained from VWR International BVBA (Leuven, Belgium). 
EMPROVE® exp L-Arginine (Ph. Eur. certified), EMSURE
® ortho-Phosphoric acid 85% 
and Ph. Eur. certified Tween 80® were obtained from Merck KGaA (Darmstadt, Germany). 
For mAb2-formulation, EMPROVE® exp sucrose (Ph.Eur.-certified) purchased from Merck 
KGaA (Darmstadt, Germany) was used. 
L-Histidine monohydrochloride monohydrate (min. 99% purity) and L-Histidine (Cell culture 
reagent) were purchased from Alfa Aesar (Karlsruhe, Germany). Di-sodium hydrogen 
phosphate dihydrate and sodium dihydrogen phosphate dihydrate were obtained from 
AppliChem (Darmstadt, Germany). Trizma® base BioXtra (>99.9%) and Trizma® 
hydrochloride BioXtra (>99.0%) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Sodium chloride was obtained from Bernd Kraft (Duisburg, Germany). Sodium 
hydroxide was purchased from Merck KGaA (Darmstadt, Germany). 
For the preparation of buffers and stock solutions, water for injection (WFI; Purelab Plus, 
USF Elga, Celle, Germany) was used.  
III.3.2 Study design 
The four different formulations, F1–F4, which were dried either by microwave-assisted 
freeze-drying (MFD) or by conventional freeze-drying (CFD), were stored for 24 weeks at 
refrigerator temperature 2–8 °C, at 25 °C (F1), and 40 °C (Table III-1). The low 
concentration mAb formulations (F1–F3) were produced using a previously described MFD 
setup with a 2 kW/2450 MHz magnetron 81, whereas the high concentration mAb 
formulation (F4) was processed using a novel semiconductor solid-state microwave 
radiation source tunable from 5 W to 450 W/2450 MHz.  
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III.3.3 Preparation of formulations 
mAb1 was dialyzed against 10 mM histidine buffer (F1, F2) or 10 mM arginine phosphate 
(F3) at pH 6.0 for 24 h using dialysis membranes Spectra/Por® (MWCO 6000–8000 Da; 
Spectrum Laboratories Inc., Compton, CA, USA) with two buffer exchanges. After dialysis, 
the concentration of mAb1 was measured with a NanoDrop™ 2000 UV photometer (Thermo 
Scientific, Wilmington, Delaware) at 280 nm using an extinction coefficient of 
ε0.1% = 1.49 g/100 mL
−1 cm−1.  
mAb2 (F4) was dialyzed and concentrated using a cross-flow filtration unit Minimate™ TFF 
capsule with omega polyethersulfone (PES) membrane (MWCO 30,000 Da; Pall 
Corporation, New York, NY, USA) by adding a 10-fold excess of 10 mM histidine buffer 
(pH 5.5). After reaching the desired volume, the concentration of the mAb was measured 
with a NanoDrop™ 2000 UV photometer at 280 nm using an extinction coefficient of ε = 
225,000 M−1 cm−1 and a molecular weight of MW = 145.5 kDa. 
Formulations were prepared according to the composition shown in Table III-1. 
Table III-1 Formulations used in this study. 
Ingredient F1 F2 F3 F4 
mAb1 [g/L] 5 5 5 / 
mAb2 [g/L] / / / 50 
Sucrose [% (w/v] 10 / / 5 
Trehalose [% (w/v)] / 10 / / 
Arginine phosphate 
[% (w/v)] 
/ / 10 / 
Polysorbate 80  
[% (w/v)] 
0.02 0.02 0.02 / 
Formulations F1 and F2 were formulated in 10 mM histidine buffer (pH 6.0), whereas F3 contained no 
additional buffer salt but was formulated and adjusted to pH 6.0. F4 was formulated in 10 mM histidine buffer 
(pH 5.5). mAB = monoclonal antibody. 
 
F1–F3 were filtered using 0.2 µm PES membrane syringe filters (VWR International, 
Radnor, PA, USA), whereas F4 was filtered using a 0.22 µm PES Sartolab® RF vacuum 
filter unit (Sartorius AG, Goettingen, Germany). For each formulation, 2.3 mL was filled in 
10R tubing vials (MGlas AG, Muennerstadt, Germany) and semi-stoppered with 
lyophilization stoppers (FluroTec® rubber stopper, West Pharmaceuticals, Eschweiler, 
Germany). The vial population for conventional freeze-drying was arranged on a 
lyophilization tray and surrounded with at least one row of 10 % (w/v) sucrose shielding 
vials. 
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III.3.4 Freeze-drying process 
All samples of a corresponding formulation were frozen in the same freezing step. The 
formulations F1–F3 were frozen in a Christ ε2-6D laboratory-scale freeze-dryer (Martin 
Christ, Osterode am Harz, Germany) with equilibration at −5 °C for 1 h, followed by 
ramping down the shelf with 1 K/min to a −60 °C set point. 
Formulation F4 was frozen in an FTS Systems LyoStar™ 3 freeze-dryer (SP Scientific, SP 
Scientific, Stone Ridge, NY, USA) with equilibration at 5 °C for 1 h, followed by ramping 
down the shelf with 1 K/min to a −50 °C set point. 
The frozen samples were subjected to one of the following drying protocols: 
III.3.4.1 Conventional Freeze-Drying (CFD) 
The conventional freeze-drying cycles are summarized in Table III-2. The freeze-dryer used 
for cycle F1 and F2/F3 was not equipped with process analytical technologies for 
sublimation endpoint determination like comparative pressure measurement. Several 
different formulations were dried in one run at the same time. The holding time for primary 
drying, therefore, was chosen to allow for completed sublimation. 
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Table III-2 Overview of the conventional freeze-drying (CFD) processes for the respective formulations. 
FD Process Setpoint Freezing 
Primary  
Drying 
Secondary  
Drying 
CFD cycle F1 TShelf [°C] 20 −5 −60 −20 0 20 
 Ramp [K/min] − 1 1 0.2 0.05 0.2 
 Hold time [min] 5 60 2580 a 2700 (1120) b − 360 
 pChamber [µbar] − − − 100 50 50 
CFD cycle F2/3 TShelf [°C] 20 −5 −60 −25 0 20 
 Ramp [K/min] − 1 1 0.2 0.05 0.2 
 Hold time [min] 5 60 3610 a 5760 (1400) b - 360 
 pChamber [mbar] − - − 100 50 50 
CFD cycle F4 TShelf [°C] 20 5 −50 −20 5 35 
 Ramp [K/min] − 1 1 1 0.15 0.3 
 Hold time [min] 5 60 1006a 1868 (1058) b − 420 
 pChamber [mbar] − − − 100 100 100 
a Freezing times were held longer than usual due to logistical reasons caused by the need to split up the batch 
before proceeding with the drying process. b Estimated time needed for complete sublimation based on the 
time the last thermocouple in the respective formulation needed to reach the shelf temperature setpoint.  
III.3.4.2 Microwave-assisted freeze-drying (MFD) 
Microwave-assisted freeze-drying was conducted on a modified laboratory-scale Püschner 
µWaveVac 0250fd vacuum dryer prototype (Püschner GmbH + Co KG, Schwanewede, 
Germany).  
For the formulations F1 – F3 the setup described previously 81 was used. Briefly, it contained 
a 2 kW/2450 MHz magnetron, a condenser (-80°C), and a vacuum system comprising a root 
pump and a rotary vane pump. The tuner, which was located between the magnetron and 
water load, was adjusted that way that approximately 1/10 of the generated microwaves went 
into the product chamber. For a schematic overview of the general setup, the reader is 
referred to reference 108. In the setup used for F1 – F3, water load and product cavity were 
interchanged. Drying was carried out at a pressure of 8 µbar to 30 µbar measured by Pirani 
gauge and at a microwave power between 23 W to 110 W measured by a HOMER™ 
impedance analyzer (S-TEAM Lab, Bratislava, Slovak Republic) until a constant mass was 
reached. The drying process used for F1 and F2/F3 is presented in Figure III-1a,b, 
respectively.  
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Figure III-1 Graphical overview of the microwave-assisted freeze-drying (MFD) processes for A F1, B 
F2/F3, and C F4. Microwave power input (MW Power) is the actual measured radiated microwave power, 
the chamber pressure is the Pirani gauge readout (pChamber), and Tc represents the readout of the glass fiber 
temperature probe. 
 
In contrast, F4 was processed with a partially modified setup comprising a semiconductor 
solid-state 500 W/2450 MHz microwave radiation source tunable from 5 W to 450 W which 
directly emitted its radiation into the product chamber.108 Moreover, the vacuum system was 
complemented by the addition of a turbopump to allow for lower chamber pressures. Drying, 
as it is shown in Figure III-1c, was carried out at a pressure of 5 µbar to 20 µbar measured 
by Pirani gauge and at a microwave power between 18 W to 99 W measured by a HOMER™ 
impedance analyzer (S-TEAM Lab, Bratislava, Slovak Republic). 
For process monitoring, two glass fiber temperature measurement probes (TS2, Weidmann 
Technologies Deutschland GmbH, Dresden, Germany) were used. Stoppering of the samples 
was carried out externally in a glove bag flushed with dry nitrogen. The dried crimped 
samples were kept refrigerated until analysis. 
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III.3.5 Karl Fischer titration 
Karl Fischer titration, equipped with a headspace module, was used to determine residual 
water content after freeze-drying. Between samples, aliquots of 9 mg and 28 mg were 
prepared in a glove box filled with pressurized air with a relative humidity of less than 10 %, 
placed into 2R vials, and stoppered. The samples were then placed in an oven with 100 °C 
to enable the fast extraction of water. The headspace moisture is transported into a 
coulometric Karl Fischer titrator (Aqua 40.00, Elektrochemie Halle, Halle (Saale), 
Germany). Results were calculated in relative water content (w/w). For verification of 
equipment performance, three aliquots of Apura® water standard oven 1 % by Merck KGaA 
(Darmstadt, Germany) were measured within a sequence. 
III.3.6 Brunauer-Emmet-Teller krypton gas adsorption 
The specific surface area of dried samples was determined using Brunauer–Emmet–Teller 
(BET) krypton gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1; 
Quantachrome, Odelzhausen, Germany). Samples of 90–200 mg were gently crushed with 
a spatula and weighed into glass tubes. Prior to measurement, an outgassing step was 
performed for at least 6 h at room temperature. An 11-point gas adsorption curve was 
measured, covering a p/p0 ratio of approximately 0.05–0.30. Data evaluation was performed 
according to the multi-point BET method fit of the Autosorb 1 software. 
III.3.7 X-ray powder diffraction  
To determine the solid-state of the lyophilizates, an XRD 3000 TT diffractometer (Seifert, 
Ahrensburg, Germany) was used. The device was equipped with a copper anode (40 kV, 30 
mA) and had a wavelength of 0.154178 nm. The scintillation detector voltage was 1000 V. 
The samples were placed on the copper sample holder and analyzed in the range of 5–45° 2-
theta, with steps of 0.05°. 
III.3.8 Reconstitution of lyophilizates 
The lyophilized cakes were reconstituted by the addition of WFI. The WFI volume for each 
formulation was calculated to match the volume of the water removed during freeze-drying. 
Reconstitution time was determined by recording the time between adding the respective 
formulation-specific volume of water for injection and obtaining a clear solution without 
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visible matter. This observation was performed by manual visual inspection. Reconstitution 
was performed applying gentle swirling for 5 s directly after the addition of water. 
III.3.9 High-performance size exclusion chromatography (HP-SEC) 
A Waters 2695 Separation module (Waters GmbH, Eschborn, Germany) equipped with a 
Waters 2487 Dual λ Absorbance Detector (Waters GmbH, Eschborn, Germany) at 214 and 
280 nm was used. Isocratic elution with a 25 mM sodium phosphate running buffer 
containing 200 mM sodium chloride (pH 7.0) was performed.  
For mAb1-formulations (F1–F3), 10 µL of a reconstituted solution corresponding to a 
loading of 50 µg protein were loaded on a Tosoh TSKgel G3000SWxl, 7.8 × 300 mm, 5 µm 
column (Tosoh Bioscience, Griesheim, Germany) and separated with a flow rate of 0.7 
mL/min.  
For mAb2 (F4), samples were diluted with 10 mM histidine buffer (pH 5.5) to 1 g/L protein 
concentration, and 25 µL was injected, corresponding to a load of 25 µg protein. A YMC-
Pack Diol-300, 300 × 8.0 mm, 5 µm column (YMC Europe GmbH, Dinslaken, Germany) 
with a flow rate of 0.8 mL/min was used for separation. Samples were measured in triplicates 
with three individual injections. Data integration of relative areas at 280 nm was performed 
using Chromeleon 6.80 (Thermo Scientific, Wilmington, DE, USA), provided that every 
peak eluting before the monomer corresponded to high molecular weight (HMW) species. 
No peaks could be detected after the monomer. For verification of equipment performance, 
an internal standard of thawed mAb formulation was injected at the beginning and end of a 
sequence.  
III.3.10 High-performance cation exchange chromatography (HP-CEX) 
A Waters 2695 Separation module (Waters GmbH, Eschborn, Germany) equipped with a 
Waters 2487 Dual λ Absorbance Detector (Waters GmbH, Eschborn, Germany) at 214 and 
280 nm was used for weak cation exchange chromatography. A linear sodium chloride 
gradient of 0% to 20% solvent B in solvent A over 30 min was used for elution at a flow rate 
of 1 mL/min. For all cation exchange (CEX) analysis, a ProPac™ WCX-10G BioLC™ 
Analytical column 4 × 250 mm equipped with a ProPac™ WCX-10G BioLC™ guard 
column 4 × 50 mm (ThermoFisher Scientific, Waltham, MA, USA) was used.  
Chapter III 
40 
For mAb1-formulations (F1–F3), the solvents were composed of A: 20 mM TRIS (pH 7.1) 
and B: 20 mM TRIS (pH 7.1) plus 300 mM sodium chloride. Reconstituted sample aliquots 
of 10 µL, corresponding to a loading of 50 µg protein, were loaded on the column.  
For mAb2 (F4), the solvents were composed of A: 20 mM TRIS (pH 7.5) and B: 20 mM 
TRIS (pH 7.5) plus 300 mM sodium chloride. Before analysis, samples were diluted with 
solvent A to 1 g/L protein concentration, and 50 µL was injected, corresponding to a load of 
50 µg protein.  
Samples were measured as triplicates with two individual injections. Data integration of 
relative areas was performed using the Chromeleon 6.80 software (Thermo Scientific, 
Wilmington, DE, USA), provided that every peak eluting before the main peak corresponded 
to acidic species and peaks eluting after the main peak corresponded to basic species. For 
verification of equipment performance, an internal standard of thawed mAb formulation was 
injected at the beginning and end of a sequence. 
III.3.11 Light obscuration 
One method used to determine subvisible particles of the formulation F1 was light 
obscuration. Therefore, a PAMAS SVSS-35 particle counter (PAMAS—Partikelmess- und 
Analysesysteme GmbH, Rutesheim, Germany) equipped with an HCB-LD 25/25 sensor, 
which had a detection limit of approximately 120,000 particles ≥ 1 µm per mL, was used. 
The pre-rinsing volume was 0.4 mL and was followed by three measurements of 0.2 mL. 
The fill rate, emptying rate, and rinse rate of the syringe were set to 10 mL/min. Before and 
between samples, the system was rinsed with WFI until less than 30 particles/mL ≥ 1 µm 
and no particles larger than 10 µm were present. Data collection was done using PAMAS 
PMA software, and particle diameters in the range of ≥1 µm to 200 µm were determined. 
All results are given in cumulative particles per milliliter. 
III.3.12 Flow-imaging microscopy 
Due to the high transparency of protein particles, an orthogonal method for subvisible 
particle determination was introduced for formulations F2–F4. Flow-imaging microscopy 
was performed on a FlowCAM® 8100 (Fluid Imaging Technologies, Inc., Scarborough, ME, 
USA) equipped with a 10× magnification cell (81 µm × 700 µm). Prior to a measurement 
set, the cell was cleaned with a 1% Hellmanex III solution and WFI. For adjustment of the 
focus, the default autofocus procedure using 20 µm calibration beads was performed. Sample 
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solution volumes of 150 µL were measured with a flow rate of 0.10 mL/min, at an image 
rate of 29 frames per second, and an estimated run time of 1.5 min. After each measurement, 
the flow cell was flushed with WFI. For particle identification, the following settings were 
used: 3 µm distance to the nearest neighbor, particle segmentation thresholds for dark pixels 
and light pixels of 13 and 10, respectively. The particle size was reported as the equivalent 
spherical diameter (ESD). Frames were collected with VisualSpreadsheet® 4.7.6 software 
and were evaluated for total particle counts of cumulative particles greater or equal to 1 µm, 
10 µm and, 25 µm per mL. 
III.4 Results 
III.4.1 Solid state 
III.4.1.1 Residual moisture content and specific surface area 
The results for residual moisture (RM) and specific surface area (SSA) determination are 
presented in Figure III-2. For the low concentrated mAb formulation with sucrose (F1), three 
different storage temperatures are shown (Figure III-2a). Directly after freeze-drying, the 
SSA results revealed identical values for CFD, 0.63 m²/g ± 0.02 m²/g, and MFD, 0.66 m²/g 
± 0.05 m²/g. Irrespective of the storage temperature and time point, neither differences nor 
relevant changes in specific surface areas were observed. With regard to residual moisture 
content, analysis showed low values for both CFD and MFD (1.1 % ± 0.1 % and 1.0 % ± 
0.5 %, respectively). These values changed only slightly over 24 weeks at all investigated 
storage temperatures. However, within the microwave-processed products, some samples 
exhibited higher variances represented by higher standard deviations, which were not found 
within the conventionally freeze-dried samples. 
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Figure III-2 Specific surface area (bars) and residual moisture content (squares) results over the course of 24 
weeks of storage at the respective storage temperature for A F1, B F2, C F3, and D F4. Values shown represent 
the mean value (n = 3) ± standard deviation. 
 
Similar results were found for the low concentrated mAb formulation stabilized with 
trehalose (Figure III-2b). No relevant differences or changes were observed for the specific 
surface area over the course of 24 weeks storage at refrigerator temperature or 40 °C. Mean 
values almost remained at initial values of 1.27 m²/g ± 0.01 m²/g and 1.22 m²/g ± 0.06 m²/g 
for CFD and MFD, respectively. In regards to residual moisture, MFD samples appeared to 
be moister than CFD samples (1.2 % ± 0.8 % vs. 0.3 % ± 0.0 %). These differences remained 
over six months of storage irrespective of the storage temperature. Yet, the moisture content 
in CFD cakes doubled at 40 °C (0.7 % ± 0.0 %), unlike MFD cakes. However, high variances 
within MFD samples may have masked such effects. 
Unlike the sucrose (F1) and trehalose (F2) formulations, low concentration mAb 
formulations with arginine phosphate (F3) exhibited differences with respect to specific 
surface area (Figure III-2c). Initial measurements directly after freeze-drying revealed values 
of 1.33 m²/g ± 0.09 m²/g and 0.95 m²/g ± 0.04 m²/g for CFD and MFD, respectively. Slight, 
but non-significant changes over storage were observed. The initially different SSA values 
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correlated inversely with the observed residual moisture mean values (CFD: 1.0 % ± 0.1 % 
and MFD: 2.8 % ± 0.4 %). A micro-collapse within MFD samples was assumed.  
F4, which was comprised of a 1:1-mixture (weight-wise) of sucrose and mAb2, was dried 
with a different microwave-setup. By this, high variances in residual moisture, which 
occasionally occurred before within MFD samples, were not observed anymore (Figure 
III-2d). For conventional freeze-dried samples, mean values changed from 1.0 % (± 0.0 %) 
to 1.2 % (± 0.0 %) over 24 weeks of storage at 40 °C. Within MFD samples, a similar 
increase from 0.4 % (± 0.0 %), initially to 0.6 % (± 0.0%), was observed after six months at 
40 °C. In contrast, specific surface areas were found to remain unaffected by accelerated 
storage conditions at values of 0.85 m²/g ± 0.15 m²/g and 0.89 m²/g ± 0.04 m²/g for CFD and 
MFD, respectively.  
III.4.1.2 X-ray powder diffraction (XRD)  
In order to confirm the amorphicity of all formulations, XRD was used. The results for the 
two sucrose-based formulations, F1 and F4, are presented in Figure SIII-1 and were directly 
compared to the pure excipient sucrose. No indications of crystallization were found.  
Amorphous halos and the absence of typical peaks 121,122 were found for trehalose-based 
formulations (Figure SIII-2). An overall XRD-amorphicity, represented by an amorphous 
halo, was also found for the significantly moister arginine phosphate formulations (Figure 
SIII-3). A reference diffractogram for recrystallized arginine phosphate was derived by 
intentionally exposing one MFD vial to a moist atmosphere overnight. 
III.4.2 Protein-related quality attributes 
III.4.2.1 Reconstitution and subvisible particles (SvP) 
Before liquid analysis, lyophilized products needed to be reconstituted. Within one 
formulation, no significant difference between the distinct drying protocols was seen. 
However, small differences with regard to other formulation were observed (Table III-3). 
Table III-3 Reconstitution times of the different formulations. 
Formulation Reconstitution Time (s) 
F1 ≤ 30 
F2 ≤ 30 
F3 ≤ 50 
F4 ≤ 120 
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The subvisible particle counts (SvP) obtained by light obscuration for F1 are presented in 
Figure III-3a,b. All vials analyzed originated from the same filtered bulk formulation, which 
is why initial particle counts were the same before a certain drying or storage scheme was 
applied. Light obscuration measurements revealed relatively low particle counts per mL of 
2212 ± 565, 26 ± 2, and 4 ± 3 for ≥1 µm, ≥10 µm, and, ≥25 µm, respectively. An increase 
of +94 % (4300 ± 546) and +49 % (3303 ± 651) for cumulative particles ≥1 µm/mL was 
observed directly after freeze-drying. In Figure III-3a the results after storage over 24 weeks 
at 4 °C and 25 °C are shown. After six months at refrigerator temperature, particle counts 
were stabilized close to values prior to freeze-drying of 2678 ± 307 (CFD) and 2227 ± 225 
for particles ≥1 µm/mL. At 25 °C storage temperature, subvisible particle counts were only 
slightly elevated for CFD (2953 ± 295), but not for MFD (1937 ± 247). No increase in bigger 
particles, ≥10 µm, and ≥25 µm, was seen at any of the storage conditions. Figure III-3b 
shows that storage over 24 weeks at 40 °C caused an increase by factor 2.3 (5106 ± 237) for 
conventionally FD, and an increase of 36 % (3003 ± 1058) for microwave-assisted FD, in 
≥1 µm particles. However, bigger variances were found for MFD samples.  
 
Figure III-3 Subvisible particle (SvP) counts for formulation F1 measured by light obscuration and size-
exclusion chromatography results. The bar charts represent the subvisible particle counts for the respective 
storage temperatures A 4 °C, 25 °C, and B 40 °C. Bars represent the mean value ± standard deviation for 
three individual vials. 
 
Figure III-4 represents the SvP counts analyzed by flow-imaging microscopy for F2. The 
same filtered bulk formulation was used for all vials analyzed. Initially, relatively low 
particle counts per mL of 1867 ± 1784, 90 ± 20 and 20 ± 35 for ≥1 µm, ≥10 µm, and ≥25 
µm, respectively, were found. A slight increase by 24% (2320 ± 599) and 37% (2549 ± 677) 
for cumulative particles ≥1µm/mL was observed directly after freeze-drying. At 4 °C storage 
temperature, particle numbers ≥1 µm/mL settled around initial values after 24 weeks, but 
the cumulative count of bigger particles increased (Figure III-4a). However, no significant 
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changes were observed. A dramatic increase for SvP ≥1 µm/mL was found over the course 
of six months at 40°C for both CFD (37909 ± 4337) and MFD (18947 ± 6753), as shown in 
Figure III-4b. The mean SvP count values for ≥10 µm and ≥25 µm also increased drastically, 
even though high standard deviations lowered the significance. However, an upward trend 
could be assumed for subvisible particles ≥10 µm/mL, in conventionally processed samples. 
 
Figure III-4 Subvisible particle (SvP) counts for trehalose-based formulation F2 measured by flow-imaging 
microscopy. Bar chart A represents the SvP counts at refrigerator storage and B at 40 °C. Bars represent the 
mean value ± standard deviation for three individual vials. 
 
The SvP counts for the low concentration mAb formulation stabilized by arginine phosphate, 
F3, are shown in Figure III-5. Prior to freeze-drying, relatively low particle counts per mL 
of 1991 ± 1490, 68 ± 42 and 20 ± 21 for ≥1 µm, ≥10 µm, and ≥25 µm were found, 
respectively. At 4 °C (Figure III-5a) storage temperature, a small increase in mean values 
for cumulative particles ≥1 µm was found over time, although particle counts for this size 
category settled around the initial values. For particles ≥10 µm and ≥25 µm, a slightly 
stronger increase in mean values was observed, although vast standard deviations lowered 
the significance.  
At accelerated storage conditions (Figure III-5b), a moderate increase in all size categories 
was seen. Especially after six months storage, the conventionally freeze-dried sample 
showed a significant increase for ≥1 µm, ≥10 µm, and ≥25 µm with particle counts per mL 
of 5913 ± 1584 (3× higher), 394 ± 97 (6× higher), and 78 ± 21 (4× higher), respectively. In 
contrast, the microwave-assisted freeze-dried sample at the same conditions showed no 
increase for ≥1 µm, and only a modest increase by factor 2.6 and 2.2 for cumulative particle 
counts ≥10 µm and ≥25 µm, respectively. 
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Figure III-5 Subvisible particle (SvP) counts for the arginine phosphate formulation F3 measured by flow-
imaging microscopy. Bar chart A represents the SvP counts at refrigerator storage and B at 40 °C. Bars 
represent the mean value ± standard deviation for three individual vials. 
 
For the formulation with 50 g/L of mAb2 and only 5 % (w/v), sucrose-stabilizer neither at 
refrigerator (Figure III-6a) nor at 40 °C storage temperature Figure III-6b), was a significant 
change in subvisible particles observed. The initial formulation before FD revealed low 
particle counts per mL of 2051 ± 1153, 40 ± 41 and 7 ± 6 for ≥1 µm, ≥10 µm, and ≥25 µm, 
respectively. The results obtained showed a larger increase by 74 % (3579 ± 2243) for CFD 
and 25 % (2555 ± 97) for MFD, in regards to cumulative particles ≥1 µm at four degrees 
celsius storage over six months, compared to storage at 40 °C.  
 
Figure III-6 Subvisible particle (SvP) counts for the high concentration mAb formulation with 50 g/L 
stabilized by sucrose, measured by flow-imaging microscopy. Bar chart A represents the SvP counts at 
refrigerator storage and B at 40 °C. Bars represent the mean value ± standard deviation for three individual 
vials. 
 
Yet, at all conditions observed, larger particle categories, i.e., ≥10 µm and ≥25 µm, revealed 
an increased number of particle counts. However, due to high standard deviations within a 
sample, no significant changes were detectable. 
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III.4.2.2 Weak cation exchange chromatography (CEX) 
In order to generically quantify different protein degradation pathways, e.g., deamidation, a 
salt-gradient weak cation exchange chromatography was used. The CEX data for F1 was not 
collected. But for the trehalose-based low concentration mAb formulation (F2), data from 
CEX measurements is shown in Figure III-7a,b for the respective storage temperatures. 
Directly after freeze-drying, irrespective of the applied drying protocol (CFD or MFD), 
relative amounts of the different species were found to be alike. For storage at refrigerator 
temperature, (Figure III-7a) acidic species dropped by roughly one percent for both drying 
protocols, whereas basic species slightly increased by 1.5 %. Somewhat more pronounced 
changes were observed for storage at 40 °C (Figure III-7b). While acidic species increased 
by three percent, basic species rose by 4.7 % and 3.5 % for CFD and MFD, respectively.  
 
Figure III-7 Relative amount of acidic and basic species obtained by high-performance (HP)-weak cation 
exchange chromatography for trehalose-based formulation F2 at A 4 °C and B 40 °C storage temperature. In 
C, the relative percentages of monomer and high molecular weight species (HMW) at the respective storage 
temperature over storage time gained by HP-size exclusion chromatography (SEC) analysis are presented. 
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For the arginine phosphate-formulation (F3), CEX data is shown in Figure III-8a,b. A small 
difference of 1.7 % in the initial relative amount of acidic species was found, which 
equalized for the two drying protocols over 24 weeks storage time at 4 °C (Figure III-8a). 
At the same conditions, basic species slightly increased for both CFD (+1.8 %) and MFD 
(+1.3 %), revealing a small deviation. Acidic species showed a noticeable change by 15.9 % 
(CFD) and 26.6 % (MFD) at 40 °C storage temperature (Figure III-8b), whereas basic 
species remained almost the same with changes by 2.5 % (CFD) and −0.5 % (MFD). 
 
Figure III-8 Relative amount of acidic and basic species obtained by HP-weak cation exchange 
chromatography for arginine phosphate-based formulation F3 at A 4 °C and B 40 °C storage temperature. In 
C, the relative percentages of monomer and high molecular weight species (HMW) at the respective storage 
temperature over storage time gained by HP-SEC analysis are presented. 
 
In the case of the high concentration mAb formulation stabilized with sucrose (F4), almost 
no differences were found between conventional and microwave-assisted freeze-dried 
products with regard to CEX results (Figure III-9a,b). At refrigerator temperature (Figure 
III-9a), changes in both species and both drying protocols ranged within less than 0.5 %. 
While similar observations were made for the acidic species at 40 °C, basic species slightly 
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rose by 2.7 % and 3 % for CFD and MFD samples, respectively. However, no difference 
between the drying procedures was observed.  
 
Figure III-9 Relative amount of acidic and basic species obtained by HP-weak cation exchange 
chromatography for the high concentration mAb formulation with 50 g/L stabilized with sucrose (F4) at A 4 °C 
and B 40 °C storage temperature. In C, the relative percentages of monomer and high molecular weight species 
(HMW) at the respective storage temperature over storage time gained by HP-SEC analysis are presented. 
III.4.2.3 Size exclusion chromatography (SEC) 
The relative amount of monomeric and high molecular weight (HMW) species was assessed 
by high-performance size-exclusion chromatography. The results of the HP-SEC analysis 
for the low concentration mAb formulation with 10 % (w/v) sucrose (F1) are displayed in 
Figure SIII-4. Irrespective of the storage temperature, no changes in monomer content 
occurred. In other words, the relative amount of monomeric species ranged between 99.0 % 
to 99.1 % at all analyzed time points, and all investigated storage temperatures.  
Only a slightly different picture was seen for the trehalose formulation F2 in Figure III-7c. 
After six months at 4 °C, the loss of monomer and the complementary rise in HMW was 
negligibly low, basically within the range of SEC sample standard deviation. A small 
decrease by −0.6 % (98.2 % ± 0.1 %) for CFD and by −0.4 % (98.4 % ± 0.1 %) for 
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microwave-assisted freeze-dried lyophilizates was observed in accelerated storage 
conditions of 40 °C for 24 weeks. 
In arginine phosphate-based monoclonal antibody formulation (F3), more changes were 
observed (Figure III-8c). At refrigerator temperature, a small decrease by less than one 
percent in monomer content, and thus, an increase in HMW aggregates to less than 2 % 
overall HMW species, occurred. However, a significant loss in monomeric content down to 
95.7 % ± 0.4 % and 96.8 % ± 0.3 % for CFD and MFD, respectively, was seen. This was 
counterbalanced by an increase in high molecular weight species to 4.3 % ± 0.4 % and 3.2 
% ± 0.3 % for conventionally and microwave-assisted freeze-dried samples. 
The formulation with 50 g/L of mAb2 (F4) showed a higher monomeric SEC-purity of 99.9 
% ± 0.0 %, compared to mAb1 formulations prior to freeze-drying (Figure III-9c). At 
refrigerator storage temperatures, only a small loss of 0.2 % relative monomer content was 
observable regardless of the initially used drying procedure. Even for 24 weeks at 40 °C, the 
monomer content for CFD and MFD samples decreased only slightly to 98.5 % ± 0.0 % and 
98.2 % ± 0.0 %, respectively. This loss was compensated by an increase in HMW to 1.5 % 
± 0.0 % and 1.8 % ± 0.0 % for conventionally and microwave-assisted freeze-dried samples, 
respectively.  
III.5 Discussion 
III.5.1 Stability with regard to solid state properties 
In the case of freeze-dried products, attributes like residual moisture content, solid state, and 
specific surface area are critical to assess and to monitor over storage and shelf-life.123 With 
respect to the specific surface area, the low mAb concentration formulations with sucrose 
and trehalose, F1 and F2 (Table III-1), showed identical values for each formulation for the 
two distinct drying protocols directly after freeze-drying and no change over the duration of 
storage. This strongly indicated the absence of a microscopic collapse, which means that the 
initially determined ice and successive pore structure remained during the two different 
drying protocols for the respective formulation.18 Regarding the residual moisture content, 
similar mean values were found for the sucrose-based formulation F1 with 1.1 % ± 0.1 % 
and 1.0 % ± 0.5 % for CFD and MFD, respectively (Figure III-2a). This moisture level was 
kept over storage, even at elevated temperatures. However, high variances in some MFD 
samples were observed. Such high variances among samples of one microwave-batch may 
have been caused by non-uniform temperature distribution. This non-uniformity in 
 
 51 
microwave heating was reported in the literature to be one major challenge associated with 
that drying technique.83,84,104 The resulting appearance of cold and hot spots was described 
as multifactorial and may be dependent on the chosen mode (multimode, single-mode) 104,124, 
oven design 83, composition and geometry of the frozen good 104,125–127, the occurrence of 
standing wave effect 128 and drying duration 129. 
In contrast, in trehalose samples (F2) residual moisture levels differ already after the freeze-
drying step, i.e. 0.3 % ± 0.0 % for conventionally dried and 1.2 % ± 0.8 % for microwave-
assisted dried samples (Figure III-2b). The CFD samples stored at 40 °C showed an increase 
to 0.7 % ± 0.0 %. This was most likely due to moisture uptake of the cake from the rubber 
stopper as it was described by Pikal and Shah 130. The equilibration of stopper moisture and 
cake moisture was found to be kinetically dependent on storage temperature in the first place. 
Because of the high variances in MFD samples, such an effect may have happened but could 
not be detected.  
An arginine phosphate-based formulation (F3) was expected to be different. Firstly, because 
of the permanently charged character of arginine which causes high dielectric loss, i.e. the 
ability of a material to absorb electromagnetic energy 104, as reported by Meng et al. 131. Of 
course, the dielectric properties of a material may vary depending on the exact composition, 
density, temperature, and frequency.104 Nevertheless, different behavior of such formulation 
within the electromagnetic microwave field was expected. Secondly, because of the reported 
complex molecular structure of arginine phosphate.132 Although the reported structure was 
described for the crystalline state, similar intense interactions in the glassy state were 
assumed.133,134 For formulation F3 specific surface area values were reduced by 39 % to 0.95 
m²/g ± 0.04 m²/g for MFD compared to 1.33 m²/g ± 0.09 m²/g for CFD initially after 
application of the different drying protocols (Figure III-2c). It is assumed that this shift in 
the SSA is associated with a microscopic collapse within the amorphous matrix which may 
have been favored by the permanently charged matrix leading to enhanced absorption of 
microwave energy.131. As the desorption step of the unfrozen water is highly SSA-dependent 
75, the micro-collapse seems likely to be the cause for higher mean residual moisture in MFD 
(2.8 % ± 0.4 %) compared to CFD (1.0 % ± 0.1 %). Over the course of storage, no significant 
change in glassy state properties was observed. 
The 50 g/L mAb2 formulation stabilized with sucrose (F4) appeared to be different with 
respect to residual moisture content (Figure III-2d). Occasionally emerging high variances 
within one sample (n = 3) produced by MFD was not observed anymore. Two possible 
reasons are: (1) the formulation which consisted roughly to an extent of 50 % of the 
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monoclonal antibody by this changing the matrix properties and (2) the newly implemented 
microwave technical setup as described in the materials and methods section. The authors 
assume that the increase in batch homogeneity within MFD samples was mainly due to the 
change in machinery setup. This is believed because: Firstly, similar formulations with the 
same mAb have been dried with the previously described MFD setup 81 and they revealed 
the same high deviations that have been observed with the low concentrated mAb 
formulations F1-F3 in this study (Table SIII-1).  
Secondly, with typical sample sizes of n = 3 potential batch inhomogeneities were 
observable. Thirdly, the semiconductor solid-state setup led to a more stable and better 
tuneable power input during the course of drying. Supportively, Bianchi et al. 135 simulated 
the physical behavior of apple slices under microwave-assisted vacuum drying processing 
comparing magnetron and solid-state technology. They concluded that with the latter an 
improved heating pattern uniformity can be achieved. 
With regard to X-ray diffraction analysis, all formulations revealed an XRD-amorphous 
solid state exhibiting an amorphous halo (Figure SIII-1 – Figure SIII-3). By that, the authors 
suppose no adverse effect of microwaves on the crystallization tendency of the investigated 
matrices. Even moister samples have not revealed any indication of recrystallization. 
III.5.2  Stability with regard to the protein 
The sucrose-based formulation with 5 g/L of mAb1 (F1) showed no clear trend in subvisible 
particles (LO) at 4°C and 25°C storage temperature (Figure III-3a) and no difference 
between CFD and MFD either. Only directly after the freeze-drying procedure an increase 
of 94 % (4300 ± 546) and 49 % (3303 ± 651) for cumulative particles ≥1 µm/mL for CFD 
and MFD, respectively, was observed. Figure III-3b shows that storage over 24 weeks at 40 
°C caused an increase by factor 2.3 (5106 ± 237) for conventionally FD and an increase of 
36 % (3003 ± 1058) for microwave-assisted FD in ≥1 µm particles. It was expected that this 
slight change in SvP at accelerated storage conditions may correlate with an increase in the 
relative amount of high molecular weight species assessed by HP-SEC. However, no such 
effect on SEC data was seen (Figure SIII-4). Across all storage temperatures and regardless 
of the used drying protocol no change in neither soluble aggregates nor loss of monomer was 
observed.  
For the trehalose-based formulation (F2) the more sensitive flow-imaging microscopy 
technique was used for subvisible particle determination (Figure III-4). Initially, low particle 
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counts per mL of 1867 ± 1784, 90 ± 20 and 20 ± 35 for ≥1 µm, ≥10 µm, and ≥25 µm, 
respectively, were found, but yet bearing unusual high variances. Directly after freeze-
drying, most likely due to freeze-drying associated stresses 4, a slight increase by 24 % (2320 
± 599) and 37 % (2549 ± 677) for cumulative particles ≥1µm/mL was observed. No 
significant changes were observed for SvP at 4 °C storage temperature (Figure III-4a). 
Taking chromatographic results into account, nor in HP-CEX (Figure III-7a+b) neither HP-
SEC (Figure III-7c) changes were observed emphasizing sufficient and comparable 
stabilization in both drying populations at 4 °C. In contrary, a dramatic increase for 
subvisible particles ≥1 µm/mL was found over the course of six months at 40 °C for both 
CFD (37909 ± 4337) and MFD (18947 ± 6753) as shown in Figure III-4b. A similarly 
pronounced increase was also for bigger particles observable, although high standard 
deviations lowered significance. Yet, an upward trend was assumed for subvisible particles 
≥10 µm/mL in conventionally processed samples. With respect to chemical degradation 
(Figure III-7b), a linear increase with shallow slope was found for both acidic and basic 
species irrespective of the drying procedure, although basic species increased slightly more 
in CFD samples. An increase in the different species can be related to several different 
changes within the protein molecule depending on primary structure, cell line, formulation 
conditions, and so forth 136–138. Reviewed by Du et al. 136 in 2012, a major contribution to 
acidic species was assigned to the deamidation reaction of asparagine residues. For basic 
species, depending on primary structure, they were discussing different causes covering 
C-terminal basic amino residues, incomplete cyclization of the N-terminal but also the 
formation of aggregates. It could be suspected that the stronger increase in high molecular 
weight aggregates (Figure III-7c) at 40 °C in CFD samples is related to the stronger rise of 
basic species in HP-CEX data. However, no follow-up investigation by (partial) protein 
digestion or by LC-MS was conducted. Nonetheless, as differences between conventionally 
dried and microwave-assisted freeze-dried samples were rather marginal, comparable 
stability in the trehalose formulation is deduced. 
Arginine phosphate as discussed in section III.5.1 was expected to be an exceptional 
formulation, especially challenging when drying with electromagnetic waves. In a recently 
published review by Stärtzel 139 several examples of successful stabilization of proteins by 
arginine salts in the glassy state were shown. Within our study, we found only tiny changes 
at refrigerator temperature with regard to subvisible particles (Figure III-5a). Primarily the 
mean values for bigger sized particles (≥10 µm and ≥25) increased after 24 weeks of storage, 
yet not significantly due to higher variances. HP-CEX data (Figure III-8a) and HP-SEC data 
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(Figure III-8c) supported this. Only slight degradation shown by relative monomer loss of 
less than 1 % in both CFD and MFD and a small increase in basic species of less than 2 % 
were found at 4 °C. At accelerated storage conditions (Figure III-5b) a moderate increase in 
all size categories was seen. Especially the conventionally freeze-dried sample showed a 
significant increase for cumulative particle counts ≥1 µm, ≥10 µm and, ≥25 µm with factors 
of 3x to 6x higher counts after six months of storage. In contrast, the microwave-assisted 
freeze-dried sample at the same conditions showed only a moderate increase by bigger 
particles ≥10 µm and ≥25 µm. Connecting that to the HP-CEX data (Figure III-8b), a 
contrary picture is drawn. One the one hand, a noticeable change in acidic species by 15.9 
% (CFD) and 26.6 % (MFD) at 40 °C storage temperature was found, whereas basic species 
remained almost the same for both drying procedures. On the other hand, HP-SEC data 
(Figure III-8c) revealed a loss in monomeric content down to 95.7 % ± 0.4 % and 96.8 % ± 
0.3 % for CFD and MFD, respectively. Taking all of that into account it appeared that the 
conventionally dried sample showed a higher degree of degradation exhibiting a higher 
increase in high molecular weight aggregates accompanied by an increased particle count in 
flow-imaging microscopy. However, HP-CEX results indicated that a moderate portion of 
the main charge variant underwent chemical reactions leading to significantly increased 
acidic species, being more pronounced in MFD samples. Stärtzel et al. 134 investigated 
different arginine salts on their stabilizing potential in the glassy state. For that, they also 
calculated the relaxation time τβ “which may be regarded as proportional to the inverse of 
molecular mobility for global motions” (Abdul-Fattah et al., 2007) 140. Subsequently, they 
related physical aggregation rate constants at 40 °C with the estimated ln(τβ). They found 
that an arginine phosphate formulation (64 g/L L-Arg, 16 g/L sucrose and 50 g/L mAb) 
revealed longer relaxation times than other arginine formulations. These relaxation times 
unexpectedly had an inversely proportional correlation to the observed aggregation constants 
by that, suggesting that increased molecular mobility had a positive effect on protein 
stability.134 This may be one explanation for the stability differences observed between CFD 
and MFD. Microwave-assisted freeze-dried samples on average revealed higher residual 
moisture content (Figure III-2c) compared to CFD. Residual water is known as a plasticizer 
of amorphous matrices which consequently also leads to increased molecular mobility 141 
and by this potentially to reduced aggregation in an arginine-based system as reported by 
Stärtzel et al.134. However, increased molecular mobility may be associated with increased 
chemical degradation 142,143 giving a potential explanation to the more distinct increase in 
acidic species MFD samples. Another explanation could be based on an advantageous effect 
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of the partial collapse in MFD samples as it was observed by Schersch et al. 144 for partially 
collapsed mannitol-sucrose formulation. All in all, microwave-assisted lyophilizates with 
arginine phosphate, on the one hand, revealed an indication for more pronounced chemical 
degradation but on the other hand, showed a less severe increase in subvisible particles and 
aggregates. The authors, therefore, conclude a comparable stability profile for CFD and 
MFD with reservations.  
For the high concentration mAb2 formulation (F4) no clear trend can be derived from 
subvisible particle analysis. Unexpectedly, particle counts at refrigerator temperature 
appeared to be higher or at a similar level compared to 40 °C after six months (Figure III-6). 
With regard to HP-CEX results, no difference between conventionally and microwave-
assisted freeze-dried samples was observed (Figure III-9a+b). In size-exclusion 
chromatography, samples stored at 4 °C exhibited a negligibly small loss of monomer for 
both drying protocols. At accelerated conditions still a rather low loss in monomeric species 
of 1.4 % and 1.7 % for CFD and MFD, respectively, was seen after six months of storage. 
For this reason, the authors conclude that both sample populations derived from the two 
respective drying protocols were comparable with respect to protein stability. 
In the future, an improved prototype dryer with a sophisticated technical setup which 
provides the operator with standard pharmaceutical freeze-drying features such as freezing 
and stoppering within the same machine is needed. A combination of current pharmaceutical 
freeze-drying equipment with modern semiconductor solid-state microwave generators is 
imaginable in the authors’ opinion. For future experiments, a look into relaxation behavior 
and potential differences between conventionally freeze-dried and microwave-assisted 
freeze-dried solids could be of interest. Thermal history is expected to be different. 
Moreover, a deeper look into potential chemical changes that may occur during MFD should 
be taken. For those analytical techniques focusing on structural changes like FT-IR and 
circular dichroism, but also methods like (peptide mapping) LC-MS should be considered. 
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III.6 Conclusion 
Microwave-assisted freeze-drying is an emerging technique recently introduced to the field 
of pharmaceutical freeze-drying of biologicals.81,105 Despite potentially huge time savings 
for vial-based drying achievable by MFD 81, we were able to elucidate comparable stability 
profiles for different monoclonal antibody formulations over storage times of 24 weeks. 
Although residual moisture contents were found to be different between CFD and MFD, no 
adverse effect on protein stability or crystallization tendency in matrices with higher residual 
moisture was found. Even the occurrence of a microscopic collapse in the microwave-
processed arginine phosphate mAb formulation (F3) did not lead to decreased stability with 
respect to the solid state- and protein-related properties. Moreover, our data indicate that 
with modern semiconductor solid-state microwave generators batch homogeneities of 
microwave batches could be approximated to those of conventional freeze-drying. However, 
the authors see a definite need for new machines complying with the requirements of 
pharmaceutical manufacturing. The new generator setup presented may open up space for 
engineering creativity to merge pharmaceutical needs with innovative heating technique.  
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III.7 Supplementary material 
 
Figure SIII-1 Representative X-ray diffractograms of sucrose-based formulation F1 and F4 compared to 
unprocessed pure crystalline sucrose (EMPROVE® exp sucrose) from the shelf. Top graphs represent 
conventionally freeze-dried samples directly after FD (left) and after 24 weeks of storage at 40 °C (right). The 
same applies to the bottom graphs but with microwave-assisted freeze-dried samples. 
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Figure SIII-2 Representative X-ray diffractograms of trehalose-based formulation F2 marked with typical 
peaks related to trehalose dihydrate (asterisk) and α-anhydrous trehalose (hash) obtained from the literature 121. 
Top graphs represent conventionally freeze-dried samples directly after FD (left) and after 24 weeks of storage 
at 40 °C (right). The same applies to the bottom graphs but with microwave-assisted freeze-dried samples. 
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Figure SIII-3 Representative X-ray diffractograms of low concentration mAb formulation with arginine 
phosphate (F3). The diffractogram of a MFD recrystallized sample of identical composition (gray line) was 
used for the identification of reference peaks. Top graphs represent conventionally freeze-dried samples 
directly after FD left) and after 24 weeks of storage at 40 °C (right). The same applies to the bottom graphs but 
with microwave-assisted freeze-dried samples. 
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Figure SIII-4 Relative percentages of monomer and high molecular weight species (HMW) at the respective 
storage temperature over storage time gained by HP-SEC analysis are presented. 
 
Table SIII-1 Residual moisture content from two similar mAb2 formulations produced with the previous 
microwave setup 81 compared to F4. 
Formulation Residual moisture content ± standard deviation 
(n=3) [%] 
F4.1: 40 g/L mAb2 +  
6% (w/V) sucrosea 
1.2 ± 0.7 
F4.2: 60 g/L mAb2 +  
4% (w/V) sucrosea 
1.2 ± 1.1 
F4 0.4 ± 0.0 
a The formulation was buffered with a 10 mM histidine buffer pH 6.0 
 
Relative standard deviations of 58 % and 92 % were found for F4.1 and F4.2, respectively. 
In strong contrast to that, F4 revealed variances and derived standard deviations which were 
in the same order of magnitude as those for CFD samples.  
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IV.1 Abstract 
The aim of this study was to investigate if mechanistically different controlled ice nucleation 
techniques in freeze-drying are comparable to each other with respect to drying process 
performance and product quality attributes. Therefore, we studied three different model 
formulations including amorphous (sucrose, trehalose) and semi-crystalline 
(mannitol:sucrose 4:1) solids containing a monoclonal antibody IgG1 (5 g/L) processed 
either by application of ice fog or depressurization technique setting an ice nucleation 
temperature of -5 °C. Subsequently, the same freeze-drying protocol on identical machinery 
was applied. The results showed that the techniques are comparable with respect to the 
thermal history of product temperature sensors and primary drying time, solid state- and 
protein-related product quality attributes. All analytics comprising Karl Fischer titration, 
XRD, and BET as well as HP-SEC, turbidity, and subvisible particle counting using flow-
imaging microscopy exhibited similarity and comparability among the controlled nucleation 
protocols.  
 
Keywords 
Freeze-Drying; Lyophilization; Protein; monoclonal antibody; Excipients; Drying; Solid-
state; Amorphism; X-ray powder diffraction (XRD) 
 
Abbreviations  
CN  Controlled ice nucleation 
FD  Freeze Drying 
FNU  Formazine nephelometric units 
HP-SEC  High-performance size-exclusion chromatography 
HPW  Highly purified water 
MWCO  molecular weight cutoff 
pchamber  Chamber pressure 
PES  polyethersulfone 
SSA  Specific surface area 
TN  Ice nucleation temperature 
TShelf  Shelf Temperature 
XRD  X-ray diffraction 
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IV.2 Introduction 
Freeze-Drying (FD) is a well-established drying process for the stabilization of biologics. 
However, long drying times 97,145 and challenges in transferability from the laboratory to 
pilot or production scale 41,67,113 are typical shortcomings of FD that increase the production 
costs. Controlling the ice nucleation temperature (TN) during freezing is a potential approach 
to overcome these downsides.40,43,55,146 Currently, there are three mechanistically different 
controlled ice nucleation (CN) techniques on the market which either (1) utilize ice seeds 
from a generated ice fog as primary nucleation sites 41,44–47; or (2) apply an overpressure 
which is rapidly released, leading presumably to cooling of liquid product surface by the 
expansion of gas, and inducing hereby ice nucleation 51,146; or (3) techniques which utilize 
vacuum-induced surface freezing by forming an ice layer due to local supercooling 147. 
Recently, the application of controlled nucleation is getting consistent attention due to its 
benefits in terms of improving lyophilization process performance 40,43,55,146 and enhancing 
product quality attributes of the protein drug product 40,43,55–58. Today there are already 
several commercially available devices for CN, and such processes are on the way to be 
submitted to the authorities for new biological entities. One major reason may be the lack of 
knowledge about the comparability of mechanistically different CN techniques in regards to 
process performance and quality of the resulting product. In fact, this puts transferability into 
question when different controlled ice nucleation techniques are used in different 
development stages. 
With our study, we aim to reduce this knowledge gap. We apply either ice fog or 
depressurization at the same TN during freezing of pharmaceutically relevant formulations 
that contain a model monoclonal antibody. Subsequently, we investigate process 
performance and product quality attributes of the resulting lyophilizates. Moreover, we 
compare the results obtained for the controlled nucleation protocols to a random nucleation 
reference batch. 
IV.3 Materials and methods 
IV.3.1 Materials 
A monoclonal IgG type 1 antibody (mAb) was kindly provided by Boehringer Ingelheim 
Pharma GmbH & Co. KG (Ingelheim am Rhein, Germany). 
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ACS certified D(+)-Sucrose was purchased from Sigma-Aldrich (Steinheim, Germany). 
D(+)-Trehalose dihydrate (min. 99 % purity) and Ph. Eur. certified D(-)-Mannitol were 
obtained from VWR International BVBA (Leuven, Belgium). L-Histidine 
monohydrochloride monohydrate (min. 99 % purity) and L-Histidine (Cell culture reagent) 
were purchased from Alfa Aesar (Karlsruhe, Germany). Di-sodium hydrogen phosphate 
dihydrate and sodium dihydrogen phosphate dihydrate were obtained from AppliChem 
(Darmstadt, Germany). Sodium chloride was purchased from Bernd Kraft (Duisburg, 
Germany). Ph. Eur. certified Tween 80® and sodium hydroxide was obtained from Merck 
KGaA (Darmstadt, Germany). For the preparation of buffers and stock solutions, highly 
purified water (HPW; Purelab Plus, USF Elga, Celle, Germany) was used. 
All excipients had analytical or higher grade and were used without further purification. 
IV.3.2 Preparation of formulations 
The mAb was dialyzed and concentrated using a cross-flow filtration cassette Vivaflow 50 
with polyethersulfone (PES) membrane (MWCO 30,000 Da; Sartorius AG, Goettingen, 
Germany) by adding a 10-time excess of 10 mM histidine buffer (pH 6.0). After reaching 
the desired volume, the concentration of the mAb was measured with a NanoDrop™ 2000 
UV photometer (Thermo Scientific, Wilmington, Delaware) at 280 nm using an extinction 
coefficient of ε0.1% = 1.49 g/100 mL−1 cm−1. To ensure reproducible starting conditions, 
identical aliquots of dialyzed mAb and excipient stock solutions were frozen at -80 °C and 
thawed overnight at refrigerator prior to the respective freeze-drying run. Formulations were 
prepared according to the composition shown in supplementary data (Table SIV-1). All 
formulations were filtered using 0.2 µm PES membrane syringe filters (VWR International, 
Radnor, PA, USA) prior to filling of the vials. 2.3 mL of each formulation was filled in 10R 
tubing vials (MGlas AG, Muennerstadt, Germany) and semi-stoppered with lyophilization 
stoppers (FluroTec® rubber stopper, West Pharmaceuticals, Eschweiler, Germany). Vials 
were arranged in the center of a lyophilization tray and surrounded with two rows of 10 % 
(w/v) sucrose shielding vials. Corresponding Tg’ values for the sucrose and trehalose 
formulation can be found in the supplementary data (Table SIV-2). 
IV.3.3 Freeze drying process 
All samples were freeze-dried using a Christ ε2-12D pilot-scale freeze dryer (Martin Christ, 
Osterode am Harz, Germany) which is capable of applying both ice fog and depressurization 
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ice nucleation technique. For the respective sample population, one of the freeze-drying 
protocols listed in Table IV-1 was applied. Product temperature was measured by wireless 
product temperature measurement probes (WTMplus, Martin Christ, Osterode am Harz, 
Germany). Secondary drying hold time was kept longer for controlled nucleation protocols 
in order to achieve acceptable low final residual moisture contents comparable to random 
nucleation processes.  
By reaching the end of secondary drying, the product chamber was backfilled with nitrogen 
to approximately 600 mbar. Vials were fully stoppered by the hydraulic press. Samples were 
crimped and kept refrigerated until analysis. 
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Table IV-1 Overview of the applied freezing and drying protocols. 
Protocol Setpoint Freezing Primary 
Drying 
Secondary 
Drying 
Random TShelf [°C] 
Ramp [K/min] 
Hold time [min] 
20 
- 
10 
- 
-5 
1 
60 
- 
-50 
1 
120 
- 
-20 
1 
2700 
0.1 
5 
0.15 
- 
0.05 
35 
0.3 
420 
0.05 pChamber [mbar] 
Ice Foga TShelf [°C] 
Ramp [K/min] 
Hold time [min] 
 
Stabilization time [min] 
 
20 
- 
10 
 
- 
 
- 
-5 
1 
55 
 
5* 
 
15* 
-5 
- 
60 
 
- 
 
- 
-50 
1 
120 
 
- 
 
- 
-20 
1 
1380 
 
- 
 
0.1 
5 
0.15 
- 
 
- 
 
0.05 
35 
0.3 
540 
 
- 
 
0.05 pChamber [mbar] 
 
Depressurizationb TShelf [°C] 
Ramp [K/min] 
Hold time [min] 
 
Stabilization time [min] 
 
20 
- 
10 
 
- 
 
- 
-5 
1 
55 
 
5* 
 
2200* 
-5 
- 
60 
 
- 
 
- 
-50 
1 
120 
 
- 
 
- 
-20 
1 
1380 
 
- 
 
0.1 
5 
0.15 
- 
 
- 
 
0.05 
35 
0.3 
540 
 
- 
 
0.05  pChamber [mbar] 
 The stabilization time and pressure setpoint marked with an asterisk were applied after the hold time stated in 
the same section. Settings for the respective ice nucleation technique were as follows: a Ice Fog: chamber 
pressure was set to 15 mbar ± 1.5 mbar with a stabilization time of 5 minutes and a subsequent introduction of 
ice crystals in the chamber by aeration through the ice condenser utilizing the external volume of the LyoCoN 
(Martin Christ, Osterode am Harz, Germany). b Depressurization: chamber was pressurized to 2.2 bar ± 0.15 
bar absolute pressure with pressurized air and nitrogen with a stabilization time of 5 minutes and a subsequent 
rapid pressure release to introduce controlled nucleation. 
 
IV.3.4 Residual moisture content 
Karl Fischer titration was used to determine residual water content after freeze-drying. 
Between 15 and 50 mg of sample aliquots were prepared in a glove box filled with 
pressurized air with a relative humidity of less than 10 %, filled into 2R vials and stoppered. 
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The samples were then placed in an oven at 100 °C to enable the fast extraction of water. 
The headspace moisture is transported into a coulometric Karl Fischer titrator (Aqua 40.00, 
Elektrochemie Halle, Halle (Saale), Germany). Results are calculated in relative water 
content (w/w). 
IV.3.5 Specific surface area 
The specific surface area of dried samples was determined using Brunauer–Emmet–Teller 
(BET) krypton gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1; 
Quantachrome, Odelzhausen, Germany). 80 – 140 mg of a sample was gently crushed with 
a spatula and weighed into glass tubes. Prior to measurement, an outgassing step was 
performed for at least 6 h at room temperature. An 11-point gas adsorption curve was 
measured, covering a p/p0 ratio of approximately 0.05– 0.30. Data evaluation was performed 
according to the multi-point BET method fit of the Autosorb 1 software. 
IV.3.6 X-ray powder diffraction  
To determine the solid state of the lyophilizates an XRD 3000 TT diffractometer (Seifert, 
Ahrensburg, Germany) was used. The device is equipped with a copper anode (40 kV, 30 
mA) and has a wavelength of 0.154178 nm. The scintillation detector voltage was 1000 V. 
The samples were placed on the copper sample holder and analyzed in the range of 5-45° 2-
theta with steps of 0.05° 2-theta. 
IV.3.7 Reconstitution of lyophilizates 
The lyophilized cakes were reconstituted by the addition of HPW. The HPW volume for 
each formulation was calculated to match the volume of the water removed during freeze-
drying. Reconstitution time was determined by recording the time between adding the 
respective formulation-specific volume of HPW and obtaining a clear solution without 
visible matter. This observation was performed by visual inspection. Reconstitution was 
performed by applying gentle swirling for 5 s directly after the addition of water. 
IV.3.8 High-performance size exclusion chromatography (HP-SEC) 
To determine relative monomer content and the relative amount of soluble aggregates HP-
SEC was used. The separation was performed on a Waters 2695 Separation module (Waters 
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GmbH, Eschborn, Germany) with a Tosoh TSKgel G3000 SWxl column (Tosoh Bioscience, 
Griesheim, Germany) using a Waters 2487 Dual λ Absorbance Detector (Waters GmbH, 
Eschborn, Germany) at 214 and 280 nm. 10 µL of reconstituted formulation with a final 
concentration of 5 g/L was injected and separated using a 50 mM PBS running buffer 
containing 300 mM sodium chloride (pH 7.0) with a flow rate of 0.7 mL/min. Samples were 
measured as triplicates with three individual injections. Data integration of relative areas was 
performed using Chromeleon 6.80 (Thermo Scientific, Wilmington, USA). An example 
chromatogram is shown in supplementary data (Figure SIV-1). 
IV.3.9 Flow-imaging microscopy 
Subvisible particles were analyzed using a FlowCAM® 8100 (Fluid Imaging Technologies, 
Inc., Scarborough, ME, USA) equipped with a 10x magnification cell (81 µm x 700 µm). 
Prior to a measurement set, the cell was cleaned with a 1 % Hellmanex III solution and HPW. 
For adjustment of the focus, the default autofocus procedure using 20 µm calibration beads 
was performed. 150 µL sample solution was measured with a flow rate of 0.10 mL/min, an 
image rate of 29 frames per second, and an estimated run time of 1.5 minutes. After each 
measurement, the flow cell was flushed with HPW. For particle identification, the following 
settings have been used: 3 µm distance to the nearest neighbor, segmentation thresholds for 
dark pixels, and light pixels of 13.0 and 10.0, respectively. Frames were collected with 
VisualSpreadsheet® 4.7.6 software and were evaluated for total particle counts of 
cumulative particles greater or equal to 1 µm, 10 µm, and 25 µm per mL. 
IV.3.10 Turbidity 
The turbidity of samples was measured as scattered laser light (λ = 860 nm) detected at an 
angle of 90 ° using a Hach Lange Nephla nephelometer (Hach Lange GmbH, Düsseldorf, 
Germany). 2.0 mL sample was gently pipetted in turbidity glass cuvettes free of particles 
with a flat bottom and placed into the device. The result is given in FNU (Formazine 
nephelometric units). 
IV.3.11 Statistical tests 
To determine variance homogeneity a Levene’s test was performed. Statistical differences 
between the means of the different applied freezing protocols were analyzed using either a 
 
 69 
one-way ANOVA-test or a Student’s t-test between two means. In all statistical tests, 
differences were considered statistically significant for p ≤ 0.05. 
IV.4 Results and discussion 
IV.4.1 Process performance  
IV.4.1.1 Nucleation and drying process 
Based on observations by the LyoCam 148, it could be seen that with both controlled ice 
nucleation techniques, i.e. ice fog (Video 1)1 and depressurization (Video 2)1 nucleation 
starts at the surface and slowly propagates bottom-down.  
The actual freeze-drying cycles for random nucleation and both CN methods are shown in 
Figure IV-1A and C, respectively. In order to produce pharmaceutically elegant cakes, an 
established standardized cycle applicable to various formulations in one run was performed. 
This cycle was adjusted to the sucrose formulation which is most prone to collapse due to 
its low Tg’. The Random nucleation process resulted in 62 h total drying time, which could 
be shortened to approximately 42 h by reducing primary drying time by 19 h (Figure IV-1A, 
bracket a) to overall 26 h time needed for sufficient sublimation as determined by wireless 
product temperature probes and differential pressure comparison. The processes in which 
depressurization and ice fog have been applied ended up with total drying times of 43 h, 
whereof 22 h were primary drying time. As secondary drying was kept longer in controlled 
nucleation samples and as settings for primary drying were kept the same among all 
processes, only a reduction of roughly 14 % of primary drying time was found compared to 
the reference process. However, process time optimization was not the main focus of this 
work, the reader interested in drying performance improvement by controlled ice nucleation 
is referred to the literature 40,43,55,57,146. Nonetheless, independent of the applied controlled 
ice nucleation technique, the thermal history of the product, and the temperature profile of 
the respective formulations as well as the time to reach a pressure difference of 0 µbar (Pirani 
vs. capacitance gauge) were found to be similar. The same was true for the nucleation 
behavior which is shown in Figure IV-1B and D for random nucleation and the controlled 
ice nucleation techniques, respectively.  
                                                 
1 The videos can be accessed via https://www.sciencedirect.com/science/article/pii/S0022354918304544#ec2  
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Figure IV-1 Freeze-drying process graphs of A random shelf-ramp freezing and C ice fog and 
depressurization. The thermocouples were placed in the formulations (Suc: sucrose, Tre: trehalose, Man:Suc: 
mannitol:sucrose) for the respective freezing protocol (Rnd: random nucleation; IF: ice fog; DP: 
depressurization). Bracket a is described in the main text. Product temperature profiles representing the 
nucleation behavior during freezing for B random shelf-ramp freezing and D the controlled ice nucleation 
protocols are shown. A small time shift between ice fog (red lines) and depressurization (blue lines) protocol 
is observable which is caused by the slightly different times needed for reaching the desired chamber pressure 
for the respective nucleation approach. 
 
A small time lag between the two controlled nucleation approaches was observable which 
was due to technical conditions related to the time needed to evacuate or pressurize the 
chamber to the desired value.  However, regardless of the CN approach, all vials were found 
to nucleate at the same time within one batch, whereas random nucleated vials show different 
degrees of super-cooling during freezing. 
IV.4.2 Solid state properties 
IV.4.2.1 Residual moisture content and specific surface area 
We found identical values for SSA in the two amorphous model formulations with either 
sucrose or trehalose (Figure IV-2A). The same is true for residual moisture which was 
identical for sucrose and only marginally different for trehalose (1.1 % vs. 1.0 % for ice fog 
vs. depressurization, respectively). Due to the higher specific surface area which facilitates 
desorption during secondary drying 75, random nucleated samples ended up with lower 
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residual moisture (0.69 % and 0.33 % for sucrose and trehalose, respectively). In contrast, 
mannitol-containing formulations only differ slightly in residual moisture content (0.43 % 
vs. 0.52 % or 0.50 % for random vs. ice fog or depressurization, respectively), but show 
different specific surface areas. Contrary to the expectations the application of controlled ice 
nucleation to mannitol:sucrose formulations resulted in the formation of larger SSA (38 % 
and 45 % increase for ice fog and depressurization in comparison to random, respectively), 
which was seen for this formulation in previous FD experiments applying controlled ice 
nucleation (Supplementary data, Figure SIV-2). This indicates a certain formulation-
dependence for the semi-crystalline model system of the effect of CN on residual moisture 
and SSA. 
 
Figure IV-2 A Specific surface area (bars) and residual moisture content (circles) for the three different 
formulations and the applied freezing protocols (Rnd: random nucleation; IF: ice fog; DP: depressurization). 
B X-ray diffractograms of semi-crystalline mannitol:sucrose formulations for the respective freezing protocol 
with characteristic markers taken from the literature149 for δ-mannitol, β-mannitol or mannitol hemihydrate at 
9.7°, 20.4° and 24.6° (blue) or 18.8° (green) or 18.0° and 25.7° (red) 2-Theta, respectively.  The shown values 
represent the mean of measurements from three different vials. Error bars indicate the standard deviation of 
the mean. 
IV.4.3 XRD 
Over the range of all applied freeze-drying protocols sucrose and trehalose formulations 
resulted in fully amorphous solids represented by an amorphous halo (Supplementary data, 
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Figure SIV-3). Model systems with mannitol contained a major fraction of δ-mannitol 
(Figure IV-2B, blue lines), a minor fraction of β-mannitol (Figure IV-2B, green line), and a 
minor fraction of mannitol hemihydrate (Figure IV-2B, red lines) independent of the freezing 
protocol. It is of particular interest, that exactly the same diffraction pattern and consequently 
the same crystalline modifications among the different freezing protocols were found. Due 
to a missing thermal treatment, metastable crystalline modifications like mannitol 
hemihydrate formed. Although this is not desired, annealing was not considered as an option 
for our approach. It potentially changes crystalline modifications. Moreover, annealing 
would have masked the generation and preservation of particularly thermodynamically 
unstable mannitol modifications.150 As annealing also allows at the same time for further 
Ostwald ice ripening, it consequently would have distorted our results. In fact, potential 
differences which would be obtained by the application of ice fog and depressurization 
would have been leveled out by annealing. 
IV.4.4 Protein analysis 
IV.4.4.1 Reconstitution time 
One reason to apply controlled ice nucleation is the potential reduction of reconstitution 
times.55,57 For the investigated formulations a time reduction was found in trehalose and 
mannitol:sucrose formulations, but not for sucrose-based lyophilizates (Supplementary data, 
Figure SIV-4). For trehalose, the effect was rather small with a reduction from 34 s for 
random nucleated samples to 18 s and 21 s after ice fog and depressurization, respectively. 
Semi-crystalline systems containing an excess of mannitol (4:1 mannitol:sucrose) showed a 
more pronounced reduction from 72 s for random nucleated samples to 45 s and 52 s 
compared to ice fog and depressurization, respectively. In contrast, no beneficial effect on 
reconstitution time was seen in sucrose samples. It was noteworthy that even at the low mAb 
concentrations in relation to stabilizer used for the present work, this time reducing effect 
was observable.  
IV.4.5 Turbidity 
Overall, low turbid samples were found (Figure IV-3, A-C, squares). A slight increase in 
turbidity due to stresses during freeze-drying was found, but no clear difference between 
different nucleation approaches was observable. 
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IV.4.6 Soluble aggregates  
In general, a small propensity for the formation of soluble aggregates was found over the 
range of all formulations directly after freeze-drying (Table IV-2).  
Table IV-2 Relative amount of monomer content and high molecular weight (HMW) species obtained by 
HP-SEC. 
Formulation Freezing Protocol Monomer (%) HMW species (%) 
Sucrose  
Initial (prior to 
FD) 
99.2 ± 0.02 0.8 ± 0.02 
Random 99.2 ± 0.08 0.8 ± 0.08 
Ice Fog 99.2 ± 0.06 0.8 ± 0.06 
Depressurization 99.2 ± 0.07 0.8 ± 0.07 
Trehalose  
Initial (prior to 
FD) 
99.1 ± 0.02 0.9 ± 0.02 
Random 99.0 ± 0.02 1.0 ± 0.02 
Ice Fog 99.2 ± 0.07 0.8 ± 0.07 
Depressurization 99.2 ± 0.07 0.8 ± 0.07 
Mannitol:Sucrose  
Initial (prior to 
FD) 
99.1 ± 0.02 0.9 ± 0.02 
Random 99.1 ± 0.09 0.9 ± 0.09 
Ice Fog 99.1 ± 0.03 0.9 ± 0.03 
Depressurization 99.0 ± 0.02 1.0 ± 0.02 
Values are expressed as the mean of triple injections out of three individual vials (n=3) ± standard deviation.   
 
Only a tiny amount of HMW formation was seen irrespective of formulation and freezing 
protocol. For this reason and due to the low mAb:stabilizer-ratio, no significant changes 
were observable directly after freeze-drying. This finding is supported by a recent systematic 
investigation by Vollrath et al.151 which showed no adverse effect of controlled nucleation 
(ice fog) on protein stability in comparison to randomly nucleated samples even after 
accelerated stability studies. Similar findings related to protein stability in short-term 
stability were reported for depressurization technique by Awotwe-Otoo and co-workers 56. 
A more pronounced decrease in protein stability by either of the investigated CN techniques, 
therefore, seems unlikely. 
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IV.4.7 Subvisible particles 
For the mannitol-containing formulation no significant difference between the investigated 
nucleation approaches was observable (Figure IV-3C, bars). In trehalose samples (Figure 
IV-3B, bars), a small shift towards higher cumulative particle counts  1 µm was found for 
controlled nucleation protocols (6192 vs. 7068 and 9151 for random vs. ice fog and 
depressurization, respectively). However, differences were not found to be statistically 
significant. Moreover, higher counts for 10 µm and 25 µm were found in random nucleated 
trehalose samples compared to CN samples whereby this difference was statistically 
significant for 10 µm comparing random nucleation with ice fog. In sucrose samples, a clear 
and statistically significant difference in cumulative particles greater or equal to 1 µm was 
observable for random nucleation compared to ice fog and depressurization (Figure IV-3A, 
bars).  
 
Figure IV-3 A-C Bars represent the cumulative subvisible particle counts per mL for sizes greater or equal 1 
µm, 10 µm, and 25 µm as a function of the nucleation approach used compared to the finally filtered initial 
formulation before freeze-drying. Turbidity is represented by squares. Values for sucrose- (A), trehalose- (B), 
and mannitol:sucrose 4:1-formulation (C) are shown in the respective graph. The shown values represent the 
mean of measurements from three different vials. Error bars indicate the standard deviation of the mean. 
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The controlled ice nucleation techniques among each other showed no significant difference 
here. With the exception that for cumulative particles  25 µm interestingly a significant 
difference between ice fog (16 ± 5) and depressurization (42 ± 18) was found. From our 
results, we assume formulation dependence for subvisible particle generation if CN is 
applied. This potential effect needs to be studied further in future experiments. 
IV.5 Conclusion 
In the present work, we compared ice fog and depressurization which are two 
mechanistically different and market-dominating controlled ice nucleation methods. With 
our study, we can confirm that regarding nucleation behavior and process length both 
techniques are well comparable. We conclude that the control of ice nucleation as such, 
compared to random nucleation, is more relevant than the applied mechanism for CN. In 
both, ice fog and depressurization, nucleation starts at the surface and slowly propagates 
bottom-down based on observations by the LyoCam 148. Therefore, vials nucleated by either 
of these CN techniques behave practically the same. In contrast, in shelf-ramp freezing, the 
nucleation typically starts at the bottom due to higher supercooling.  
In conclusion, we could show that the resulting product is with respect to solid state 
properties practically identical over the range of investigated pharmaceutically relevant 
formulations. From our results, this is also true for soluble aggregates and turbidity measured 
directly after freeze-drying. We, therefore, assume that a process transfer from one to another 
controlled ice nucleation technique will be applicable without major challenges caused by 
the nucleation mechanism which may be different in nature. Based on our results, both ice 
fog and depressurization lead to similar process performance and similar critical product 
quality attributes. A change of the applied CN technique during process transfer and scale-
up is therefore assumed to be of generally low risk, irrespective of usual scale-up challenges. 
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IV.6 Supplementary material 
IV.6.1 Materials and methods 
Table SIV-1 Overview of the different investigated formulations. 
Formulation 
mAb 
[g/L] 
Sucrose 
[% (w/v)] 
Trehalose 
[% (w/v)] 
Mannitol 
[% (w/v)] 
Polysorbate 80 
[% (w/v)] 
Sucrose 5 10 - - 0.02 
Trehalose 5 - 10 - 0.02 
Mannitol:Sucrose 5 2 - 8 0.02 
All stock solutions used were prepared in 10 mM histidine buffer (pH 6.0) The mAb stock solution was 
dialyzed in 10 mM histidine buffer (pH 6.0), too.  
 
IV.6.1.1 Dynamic scanning calorimetry (Tg’) 
The glass transition temperature of the liquids prior to freeze-drying was measured using a 
Mettler Toledo DSC 821e (Gießen, Germany) dynamic scanning calorimeter. 25 µL of the 
formulation was pipetted in an aluminum crucible and crimped. A DSC method cooling from 
20 °C to -50 °C with a cooling rate of 10  K/min, followed by an isothermal step for 5 
minutes and a subsequent ramping to 20 °C with 10 K/min was used. The glass transition 
temperature of the maximally freeze-concentrated solution was evaluated from the heating 
step as the inflection point of the glass transition using the Mettler StarE Software. 
Table SIV-2 Glass transition temperatures of the maximally freeze-concentrated solutions of the amorphous 
formulations used. 
Formulation Tg’ onset (°C) Tg’ inflection point (°C) 
Sucrose -34.6 ± 0.2 -33.1 ± 0.3 
Trehalose -31.7 ± 0.1 -30.4 ± 0.2 
Values are expressed as the mean of three individual measurements (n=3) ± standard deviation. 
 
 
 77 
 
Figure SIV-1 Example HP-SEC chromatogram showing the method of peak separation and integration. HMW 
represents the relative fraction of high molecular weight species whereas monomer depicts the relative area of 
the monomer peak. There was no peak eluting later than the monomer in any analyzed sample. 
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IV.6.2 Results 
IV.6.2.1 Specific surface area (previous experiment) 
As shown in Figure SIV-2 the same unexpected enlarged SSA was observed for the two 
controlled ice nucleation techniques in a previous experiment (Figure SIV-2, Experiment 1). 
Despite holding times during the FD process, all other settings (TN, exact formulation, 
freezing/drying protocol) were the same. 
 
Figure SIV-2 The specific surface area data for mannitol:sucrose 4:1-formulation from a previous experiment 
(left) and the one described in the main body (right). The shown values represent the mean of measurements 
from three different vials. Error bars indicate the standard deviation of the mean. 
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IV.6.2.2 X-ray diffraction of sucrose and trehalose formulations  
Independent of the applied freezing protocol sucrose and trehalose formulations ended up as 
fully amorphous solids represented by an amorphous halo in x-ray diffractogram (Figure 
SIV-3). 
 
Figure SIV-3 Representative x-ray diffractograms for the respective formulations and freezing protocols. 
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Figure SIV-4 Reconstitution times obtained for the respective formulation and the corresponding freezing 
protocol. The shown values represent the mean of measurements from three different vials. Error bars indicate 
the standard deviation of the mean. 
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Chapter V Study on key variables that can influence 
controlled ice nucleation in a pilot-scale 
freeze-dryer 
Abbreviations 
API  Active pharmaceutical ingredient 
CN  Controlled ice nucleation 
HES  Hydroxyethyl starch 
PES  Polyethersulfone 
SV-ratio  Liquid surface area to fill volume-ratio 
TN  Nucleation temperature 
TS  Shelf temperature setpoint  
WFI  Water for injection   
 
V.1 Introduction 
Freeze-drying is an established unit operation used in the production of parenteral products, 
e.g. biologics. The current commercial freeze-drying processes rely on random ice 
nucleation events during the freezing step. Such stochastic nucleation is reported to bear a 
potential for batch heterogeneity with respect to product characteristics and moisture content 
within the same batch.43,54 Controlled ice nucleation holds a great promise to reduce those 
inter-vial variations that arise from the freezing step. That is why the control of the nucleation 
temperature (TN) during the freezing step of pharmaceutical freeze-drying constantly gained 
interest over the last two decades. Controlled ice nucleation (CN) as such refers to the control 
of TN of all vials and thus control of the degree of supercooling of the filled solution by 
introducing a stimulus to the supercooled solutions. Several techniques are reported in the 
literature, some of them with commercial implementation. The most common techniques are 
based on (1) the introduction of ice seeds by ice fog 41,44–49, (2) the application of rapid 
pressure changes 48,50,51, or (3) the application of vacuum to induce local surface freezing 52–
54. Although the benefits and advantages of controlled ice nucleation from a process time 
40,43,50,52,53,55, batch, and/or product quality perspective 40,43,54–59 have been shown widely, 
shelf-ramp freezing is still the gold standard in most (commercial) processes. A better 
understanding of the factors important for a successful CN process and their effects on the 
product quality will be vital for the implementation of controlled ice nucleation technique in 
commercial manufacturing.  
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The risk of failure of the CN step is likely if the critical variables are not well controlled and 
within a certain range as it was reported by a process scientist (personal communication). 
During process characterization studies, they observed a floating phenomenon occurring 
after the induction of controlled ice nucleation. Observed was the literal floating of a frozen 
layer on top of a liquid-like layer and in some cases even a complete melting of the initially 
frozen solution was seen. Similar observations with regard to floating were also reported by 
Oddone et al. 54. At this point, it is important to look into the physics of freezing and 
supercooling. Searles et al. 18 divided the freezing of water (which in general is the main 
component of pharmaceutical solutions to be freeze-dried) into four steps which comprise 
(1) the cooling of the solution below its equilibrium freezing temperature, i.e. supercooling, 
(2) the formation of an ice nucleus, i.e. primary nucleation, (3) the instant subsequent growth 
of an ice nucleus to ice crystals, i.e. secondary nucleation, and (4) the final solidification by 
the completion of the liquid-to-solid phase transition by proceeding ice crystal growth. The 
supercooled solution is metastable and is therefore prone to spontaneous crystallization of 
ice. The higher the degree of supercooling the more the number of ice nuclei increases and 
thus the probability of ice crystallization 18–21. In the case of CN, the (secondary) 
nucleation/crystallization is induced by the introduction of a stimulus. When the nucleation 
event occurs, the temperature of the liquid-solid mixture increases close to the equilibrium 
freezing point and the crystallization stops due to the lack of sufficient removal of heat of 
crystallization. Because of this, only a portion of the crystallizable water instantly freezes 
during secondary nucleation. Searles et al. 18 calculated that only around 7 % of the freezable 
water could have crystallized at a nucleation temperature of -5 °C in an aqueous solution of 
10 % (w/v) HES. The biggest amount of water crystallization follows with continuous heat 
removal.21,152 Consequently, the degree of supercooling and the subsequent continuous heat 
removal, e.g. during an isothermal post-CN hold step is critical to a controlled ice nucleation 
process. Whereas the nucleation temperature mainly determines the ice morphology and 
thereby the process performance during the subsequent drying steps 18, the post-CN hold 
step may have implications on both ice crystal properties (ice crystal size, complexity of the 
ice network) and API integrity. The impact on ice crystal properties is mainly due to Ostwald 
ripening which leads to a decreased interfacial free energy due to a melting of smaller ice 
crystals in favor of larger ice crystals.21,22,153 In the case of the incorporated API, the 
isothermal post-CN hold step may play a role with regard to damages resulting from freeze-
concentration and/or cold denaturation of protein APIs.11,20,31,154 
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Two recent studies elucidated the interplay of nucleation temperature and the post-CN hold 
step on product morphology and process-related parameters. Oddone et al. 54 on the one hand 
investigated the influence of different TN and post-CN shelf temperatures on a 5% mannitol 
placebo with different filling volumes using vacuum-induced surface freezing. They 
described a floating of an ice layer on a liquid-like phase when applying TN = - 5 °C and 
observed signs for a meltback if the post-CN shelf temperature was kept at this temperature. 
In contrast, they found the formation of ice filaments (dendritic structures) when a vial with 
a high filling volume (corresponding to a filling height of 1.7 cm) was nucleated at -5 °C 
with a subsequent lowering of the Ts to – 10 °C, by this leading to an inhomogeneous middle 
section of the lyophilized cake. Wenzel et al. 155 on the other hand investigated a buffered 
system containing 100 g/L of S-Adenosyl-L-methionine disulfate tosylate with 
approximately 1.5 cm filling height in 10R vials. They applied different controlled 
nucleation protocols using depressurization with a special focus on post-CN hold time. At 
this, they found a general trend towards lower product resistance values for higher Ts, but 
also indications for local micro-collapse with an unfavorable morphology for the highest Ts 
of -3°C followed by an isothermal hold step at the same shelf temperature setpoint.  
Considering the issues with controlled ice nucleation that were reported in literature, it 
appears important to study the variables affecting the CN process, on the one hand, to better 
understand the process and interplay of factors, on the other hand to pave the way for the 
implementation of this technique for the production of drug products. That is why our study 
aims to provide further insight in the factors for the process characterization of controlled 
ice nucleation. Significant factors influencing the successful performance of CN should be 
identified. Moreover, the occurrence of unfavorable events like floating and therewith 
(some) error limits should be reproduced and studied. 
We hypothesize that the appearance of failures during the controlled ice nucleation process 
is related to an unfavorable combination of different factors. These are versatile and may 
include, but are not limited to:  
 the vial (vial type, size, stopper type), 
 the formulation (filling volume and filling height, composition, total solute 
concentration, solution viscosity, solution density, class of API) 
 the nucleation process (cooling ramp and isothermal hold time before CN, features 
associated with the used technology, nucleation temperature, post-CN hold time and 
temperature, cooling ramp down to final freezing temperature) 
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In our study, we investigated placebo sucrose solutions for some of the aforementioned 
factors which we considered to be the most critical for the occurrence of failure during 
controlled ice nucleation. 
V.2 Materials and methods 
V.2.1 Materials 
For the representative placebo formulations, the following excipients were used: 
EMPROVE® exp D(+)-sucrose (Ph.Eur.-certified) and sodium hydroxide purchased from 
Merck KGaA (Darmstadt, Germany), L-Histidine monohydrochloride monohydrate (min. 
99% purity) and L-Histidine (Cell culture reagent) supplied by Alfa Aesar (Karlsruhe, 
Germany). Methyl blue microbiology stain BHD prolabo (C.I. 42780) was purchased from 
VWR International BVBA (Leuven, Belgium). For the preparation of buffers and stock 
solutions, water for injection (WFI; Purelab Plus, USF Elga, Celle, Germany) was used.  
V.2.2 Formulations 
The stock solutions of L-histidine buffer, methyl blue and sucrose were mixed in a way to 
obtain the final placebo formulations covering a range of 5.2 % (w/v) to 15.2 % (w/v) total 
solute concentration as summarized in Table V-1 Formulations used in the study. The 
respective filling volume was filled in 10R tubing vials (MGlas AG, Muennerstadt, 
Germany) and semi-stoppered with lyophilization stoppers (FluroTec® rubber stopper, West 
Pharmaceuticals, Eschweiler, Germany).  
Table V-1 Formulations used in the study. 
Formulation L-Histidine buffer [mM] Sucrose [% (w/v)] Methyl blue [ppm] 
5 % Sucrose 10 5 5 
10 % Sucrose 10 10 5 
15 % Sucrose 10 15 5 
The L-histidine buffer was adjusted to pH 5.5. 
V.2.3 Experimental setup 
All experiments were conducted on an FTS Lyostar III pilot-scale freeze-dryer (SP 
Scientific, Stone Ridge, NY, USA) using the upper and the middle shelf. The product 
temperature was monitored in one vial of each factor combination placed on the outer edges 
of all loaded vials using wired thermocouples (Type T, Newport Electronics, Deckenpfronn, 
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Germany). For the induction of controlled ice nucleation, the ice fog method described by 
Geidobler et al. 49 was used. Briefly, the shelves loaded at room temperature were ramped 
down to the respective shelf temperature setpoint with 1 K/min and held for 1h to allow for 
equilibration and supercooling. Subsequently, the freeze-dryer was evacuated to roughly 4 
mbar and held depressurized for another 5 min to allow for product temperature equilibration 
and to ensure 100 % nucleation success among the investigated vials. Hereafter, the system 
was rapidly raised to atmospheric pressure by opening the release valve which ventilated via 
the cold condenser resulting in almost instant nucleation of the supercooled vials. Nucleation 
success was determined visually. 
For each shelf temperature setpoint and for each response, a separate run was performed, i.e. 
six runs in total. 
V.2.3.1 Residual accessible liquid volume 
The vials were placed in the first third of the upper and middle shelves in a central position 
from the acryl glass door. In order to reduce the radiation effects of the chamber wall, a 
dummy vial row was placed around the investigated vials. At a desired sampling time point 
after induction of ice nucleation, one vial per shelf was taken out and immediately analyzed. 
For that, the liquid portion of the vial content was gently poured either into a 2 mL Eppendorf 
tube with 0.1 mL marks (Eppendorf AG, Hamburg, Germany) or into a 10 mL measuring 
cylinder with 0.2 mL marks assuring that no ice or slush was poured into the cylinder.  
V.2.3.2 The thickness of the frozen layer 
Ten vials, of which the outer were equipped with thermocouples, were placed in the front 
center of each shelf close to the acryl glass door. A white background was placed behind the 
vials. Two rulers were attached to the shelves on the left and right sides of the vials. In front 
of the acryl glass door of the product chamber, a Nikon digital camera D5300 (Nikon GmbH, 
Düsseldorf, Germany) equipped with a Nikkon DX AF-S Nikkor 18-105 objective was 
mounted on a tripod. The camera settings were set to ISO 640, aperture 7.1, exposure time 
1/80, and manual focus. To assure for uniform illumination of the photograph, two led 
spotlights were attached to the acryl glass door. With the induction of ice nucleation, an 
interval photo series was started with a picture taken every minute. Each picture was 
processed using ImageJ (Version 1.8.0_112, NIH, USA). The raw file was split into the RGB 
channels, of which the green channel was used for scaling (pixel/cm). For improved 
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differentiation between transparent liquid and blurry frozen layer, the contrast was increased. 
Eventually, the height of the frozen layer was determined on an individual vial basis. The 
two values per process condition of one shelf were averaged and taken as one replicate. 
V.2.4 Design of experiments 
To systematically investigate the impact of different factors and second-order interactions, 
an experiment plan using a general multi-stage full factorial design was created. The 
software Minitab 19 Statistical Software (Minitab, LLC., State College, PA, USA) was used.  
V.2.4.1 Factors 
From the factors identified in the introduction, those assumed to be most critical are summed 
up in Table V-2 and were considered in the study design. 
Table V-2 Factors included in the general multi-stage full factorial design 
Factor Unit Type Levels 
Shelf temperature 
setpoint 
°C quantitative -3, -7a, -10 
Liquid surface 
area to fill 
volume-ratio1  
1/cm quantitative 0.5, 0.8a, 1.0 
Total solute 
concentration 
% (w/v) quantitative 5.2, 10.2a, 15.2 
Post-CN hold 
time 
min multilevel 
10, 20, 30, 60, 75, 90, 
120 
1 In the following text referred to as Surface-Vol liquid ratio or SV-ratio. a ”Center point” which was added 
manually to the study design. 
 
The shelf temperature setpoint was used as a freeze-dryer build-independent and 
reproducible surrogate for the product temperature and therewith as a surrogate for the 
nucleation temperature TN. 
The term liquid surface area to fill volume-ratio (SV-ratio) was introduced as a generic vial 
size-independent term covering aspects of vial format and filling height which in turn is 
dependent on the filling volume of the vial. For the determination of the respective value, 
the area of the circle of the inner cylinder of a 10R vial was calculated using: 
 
𝐴 =  𝜋 ∗ 𝑟2  (Equation V-1) 
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with A representing the surface area and r reflecting the inner radius of the cylindric part of 
the glass tube, i.e. r = 2.2 cm in the case of 10R as stated by the glass vial manufacturer 
SCHOTT 156. Furthermore, the complementary filling volumes of filling heights 1.0 cm, 1.4 
cm (center point), and 2.0 cm were empirically determined to be 3.8 mL, 5.32 mL, and 7.6 
mL, respectively. Herewith, the SV-ratio could be calculated using: 
𝑆𝑉 − 𝑟𝑎𝑡𝑖𝑜 =  
𝜋∗𝑟²
𝑉(𝑓𝑖𝑙𝑙𝑖𝑛𝑔) 
 (Equation V-2) 
 
resulting in SV-ratios of 0.5, 0.71, and 1.0 for filling heights of 2 cm, 1.4 cm, and 1 cm, 
respectively.  
The total solute concentration represented the overall amount of solutes included in the 
formulation, which comprised buffer components, sucrose and methyl blue. 
The post-CN hold time reflected the time duration starting from the nucleation stimulus. For 
the stated duration, the shelf temperature setpoint was kept at the same setting used for the 
initiation of ice nucleation in order to separate effects which may have been caused by a 
temperature ramp after initialization of the nucleation. 
V.2.4.2 Responses 
The occurrence of the floating phenomenon and the investigation of the error limits of the 
controlled ice nucleation process was rarely reported in the literature and was mainly 
concerning nucleation success in general 21. Therefore, the best fit responses are not known 
yet. To be able to prioritize impacting factors, quantitative and easy to assess responses were 
needed. In this experiment, we investigated two responses in placebo solutions which will 
be described in the following: 
 Relative residual accessible liquid volume 
 Relative thickness of the frozen layer 
The occurrence of floating of a solid ice layer on top of a liquid layer implies a portion of 
the filling volume to be in a liquid-like physical state. For the data set underlying the 
response relative residual accessible liquid volume, the measured volume of a vial was set 
in relation to the filling volume of the respective vial leading to a value between 0.0 and 1.0. 
Two replicates of each condition were included in the investigation. 
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The relative thickness of the frozen layer was determined by the evaluation of photographs 
taken in a standardized setup (see V.2.3.2). The number of pixels was transformed into a 
height allowing to measure the thickness of the frozen layer. This value was set in relation 
to the known filling height of the respective vial. Two replicates of each condition were 
included in the investigation. 
V.2.5 Regression model  
All obtained data was fit to a regression model using Minitab statistical software. 
V.2.5.1 Relative residual accessible liquid volume  
In order to obtain normally distributed data, a constant of c = 0.01 needed to be added to 
allow for a box-cox power transformation with a λ = 0.5. By that, the square root of the 
original values was calculated leading to a normally distributed data set. All factors and 
factor combinations up to second-order interactions were included. A two-sided 95 % 
confidence interval was used. The model generation was performed by stepwise regression, 
i.e. that the software automatically added and removed terms to the model to identify a useful 
subset of the terms. The specified alpha error values to enter or to remove a term from the 
model based on a comparison to its p-value were set to 0.15 each. This model was analyzed 
for unusual observations, which are single value combinations that do not follow well the 
proposed regression equation and which are characterized by absolute standardized residuals 
greater than 2. The model was adjusted by excluding seven observations based on the 
standardized residuals. Eventually, the model terms were checked for statistical significance 
based on α = 0.05 which led to no change in the model terms. The second-order regression 
model for the response relative residual accessible liquid volume was represented by the 
following equation: 
(Relative residual accessible liquid volume + c)^0.5 = 1.178 - 0.530 Surface-Vol 
liquid-ratio + 0.0721 Shelf Temperature Setpoint - 0.01054 Post-CN hold time + 0.03068 
Total solute concentration + 0.000042 Post-CN hold time*Post-CN hold time - 0.0383 
Surface-Vol liquid-ratio*Shelf Temperature Setpoint - 0.000314 Shelf Temperature 
Setpoint*Post-CN hold time + 0.002847 Shelf Temperature Setpoint*Total solute 
concentration 
(Equation V-3) 
 
 
 89 
The final model showed a corrected R² of 77.1 % and a prognostic R² of 75.1 %.  
V.2.5.2 The relative thickness of the frozen layer 
The obtained data were evaluated for the response as described above. It turned out that the 
factor combination of the highest shelf temperature setpoint (TS = -3 °C), the biggest filling 
volume represented by the SV-ratio 0.5, and highest total solute concentration (15.2 %) 
showed a decrease in the response over time regarding the thickness of the frozen layer. That 
resulted in a clear liquid solution after approximately 50 minutes of observation. As this was 
an artificial effect caused by the 5 minutes holding step at vacuum conditions before 
induction of the nucleation, the dataset based on that factor combination was excluded from 
the model generation. 
All factors and factor combinations up to second-order interactions were included. A two-
sided 95 % confidence interval was used. The model generation was performed by a stepwise 
regression with alpha values of 0.15. This generated model was adjusted by excluding seven 
observations based on the standardized residuals. Eventually, the model terms were checked 
for statistical significance based on α = 0.05 which led to no change in the model terms. The 
regression model for the response relative thickness of the frozen layer was represented by 
the following equation: 
 
Relative thickness of the frozen layer = 0.6426 + 0.2564 Surface-Vol liquid-ratio - 
0.01955 Shelf Temperature Setpoint + 0.000732 Post-CN hold time + 0.02138 Total solute 
concentration - 0.002451 Total solute concentration*Total solute concentration + 0.02564 
Surface-Vol liquid-ratio*Shelf Temperature Setpoint + 0.000128 Shelf Temperature 
Setpoint*Post-CN hold time - 0.002598 Shelf Temperature Setpoint*Total solute 
concentration + 0.000046 Post-CN hold time*Total solute concentration 
(Equation V-4) 
 
The final model showed a corrected R² of 75.4 % and a prognostic R² of 71.1 %.  
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V.3 Results and discussion 
V.3.1 Occurrence of floating  
During all experiment runs, no clear floating phenomenon as described in the introduction 
could be reproduced. However, an iceberg formation was seen at one condition setting which 
is speculated to be caused by floating (see section V.3.3). 
V.3.2 Effect of the investigated factors on the responses 
To increase the quality of the fit of the model, second-order interactions were taken into 
account within the model. However, in the following only the statistically significant single 
factors are taken into consideration. The extent and direction of the factors on the respective 
response are shown in Figure V-1 and Figure V-2.  
 
Figure V-1 Factor diagrams for the response relative residual accessible liquid volume. 
 
For mitigation of a failure during controlled ice nucleation, the relative residual accessible 
liquid volume is ought to be minimized with a certain setting, i.e. a value close to 0 was 
desirable for this response. It is important to note that the curvature of the post-CN hold 
time-line is likely to be caused by the not normally distributed data or by artefacts in the data 
set. Therefore, only the sign of the slope is taken into consideration. Derived from Figure 
V-1 lowering the shelf temperature setpoint and keeping the post-nucleation hold time 
between 50 minutes and 100 minutes seemed to have the strongest effect on a reduction of 
the response. Reducing the filling height (represented by the SV-ratio) and decreasing the 
total solute concentration also appeared to lead to a reduced relative residual accessible 
liquid volume, although the impact seemed to be lesser than for shelf temperature setpoint 
and post-CN hold time. 
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Concerning the optically measured response, partially concordant results were found (Figure 
V-2).  
 
Figure V-2 Factor diagrams for the response relative thickness of the frozen layer. 
 
In that case, a value of the response close to 1.0 was desirable. Like with the residual liquid 
volume, the impact of a lowered shelf temperature setpoint appeared to have a strong impact. 
However, the influence of the post-CN hold time was not found to be as strong as for residual 
volume. Yet, a longer hold time appeared to lead to increased frozen layer thickness. The 
SV-ratio showed the same trend as for the residual volume, i.e. that a lower filling height 
increased the thickness of the frozen layer. An artificial finding caused by the results for the 
manually added “center point” was seen with respect to the total solute concentration. Here, 
it appeared that a solute concentration close to 10 % would maximize the thickness of the 
frozen layer (Figure V-2, right graph). This supposed correlation should be taken with 
caution due to a possible artefact in the model caused by the manually added center point.  
V.3.3 Implications for controlled ice nucleation process design 
Based on the unclear suitability and reproducibility of the investigated responses and other 
potential blind spots of the experimental setup (see section V.3.5), all results should be 
interpreted carefully. However, for the factor combination with the lowest solute 
concentration of 5.2 %, a time-dependent growth of an iceberg-like spike on top of the frozen 
good was seen (Figure V-3). 
Chapter V 
92 
     
1 min 30 min 60 min 90 min 120 min 
Figure V-3 Photographs showing the time-dependent formation of an iceberg (red arrows) on top of the 
frozen good for the factor combination: SV =.0.5, TS = -3 °C, total solute concentration = 5.2 %. The black 
arrows point to the area which becomes clearer over holding time. 
This could only be observed for that factor combination assumed to be unfavorable regarding 
filling height (SV-ratio) and insufficient removal of heat of crystallization represented by 
the high shelf temperature. It is speculated that this iceberg-like formation (Figure V-3, red 
arrows) may have been caused by floating of a large frozen portion on a small liquid residue 
(Figure V-3, black arrows). The spike formation already started between 30 min and 60 min. 
Looking at the raw images, a change in the surface appearance of the top layer of the frozen 
good was first seen after approximately 45 min. The occurrence of such an optical defect is 
undesirable and should, therefore be avoided during controlled ice nucleation either by 
reduction of the filling height or by decreasing the shelf temperature setpoint. 
Based on that, an acceptable range for the responses for the generation of overlaid contour 
plots was defined. The overlaid contour plots help to visually identify an area where the 
predicted means of the two response variables are likely to be in an acceptable range (Figure 
V-4). Bearing in mind, that the model-based assumptions should be considered rather 
qualitative than quantitative, some implications for the controlled ice nucleation process 
design could be assumed. The graphs A to C (Figure V-4) all represent the case of 2 cm fill 
height (SV-ratio 0.5) and an increasing solute concentration from 5.2 % to 15.2 %, 
respectively. For that high filling height, rather low shelf temperature setpoints should be 
chosen, decreasing with an increasing total solute concentration. Concerning the hold time 
after the CN stimulus, a longer time would appear to be beneficial. However, the iceberg 
observations made above should be considered, too. Consequently, a longer holding time 
(i.e. approximately > 30min) in combination with the highest technically possible shelf 
temperature setpoint regarding the successful induction of ice nucleation, should be avoided.  
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Figure V-4 Overlaid contour plots for both responses. the y-axis represents the shelf temperature setpoint 
and the x-axis represents the post-CN hold time. All other factors are fixed at different levels from A to F. 
The red line refers to the response relative residual accessible liquid volume with its set lower limit (solid 
line) and upper limit (dashed line). The blue line corresponds to the response relative thickness of the frozen 
layer with its set lower limit (solid line) and upper limit (dashed line). The area marked in white in a graph 
represents the operational area where the predicted means of the two response variables are within that 
acceptable range. 
The more likely use case of 1 cm filling height (SV-ratio 1), is represented in the graphs D 
to F (Figure V-4) for an increasing solute concentration from 5.2 % to 15.2 %, respectively. 
It could be assumed that with lower filling heights, higher shelf temperature setpoints are 
feasible. Interestingly, the model suggests that with increasing solute concentration the shelf 
temperature setpoint should be lowered, too, to ensure a successful nucleation process. 
V.3.4 Recommendations for controlled ice nucleation process design 
Mainly based on relevant recent literature reports by Oddone et al.54 and by Wenzel et al.155 
and partly supported by the our data discussed in section V.3.3, the following 
recommendations can be made: 
 filling heights of significantly more than 1 cm (i.e. 1.5 cm and more) should be 
avoided to decrease intra-vial heterogeneity and micro-collapse independent of the 
vial size 54,155,157 
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 high shelf temperature setpoints close to the equilibrium freezing point (e.g. -3 °C) 
during post-CN hold time should be avoided to prevent the system from significant 
viscous flow and meltbacks (Oddone et al., 2016 54 and the presented results) 
 (too) low shelf temperature setpoints during post-CN hold time (e.g. -20 °C) should 
be avoided as they could be linked to the unfavorable occurrence of micro collapse 
and inter-vial heterogeneity due to faster removal of heat of crystallization during 
secondary nucleation 54,155 
And, although not investigated in this study, but of importance particularly in relation to 
process transfer and scale-up and thus worth mentioning as a general recommendation: 
 controlled ice nucleation process transfer from depressurization to an ice fog method 
seems to be feasible 48, whereas depressurization and vacuum-induced surface 
freezing does not seem to be interchangeable without major challenges 155  
V.3.5 Limitations and blind spots of the study 
With the presented approach, we studied one path in the direction of a systematic 
investigation of the error limits of CN. The phenomenon of floating only occured in one 
factor combination. This may be due to some limitations and blind spots the presented work 
implies. Ambient factors like radiation from the chamber walls and acryl glass door that 
could not be controlled should have been mitigated, e.g. by standardization or sufficient 
knowledge from preliminary experiments, as far as possible. The general multi-stage full 
factorial design could have been replaced by a first screening design to identify significant 
factors with suitable limits and levels. These factors could have included different vial 
formats and filling volumes to overcome the generic SV-ratio which may be oversimplified. 
Additionally, formulation aspects not only limited to the total solute concentration but also 
to include polymer content (representing a monoclonal antibody) and viscositycould have 
been of interest. Concerning the responses, there is a high need for a suitable, directly 
quantitatively measurable and accurately determinable variable as the used responses may 
not be per se suitable to identify correlations and to investigate all suitable operational 
spaces. Especially the provisional character of the introduced response variables lacking a 
high level of objectification and standardization may adversely impact the quality of the 
regression model. The regression model itself was chosen as simple as possible only 
incorporating terms to second-order. 
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V.4 Conclusion and outlook 
In this preliminary work, we studied different factors that potentially affect the success of 
the controlled ice nucleation step in order to broaden the knowledge about the CN process. 
We introduced two new and highly experimental response variables to determine the effects 
of several factors on the freezing behavior of selected sucrose-based placebo formulations. 
The generated regression model suggested a strong influence of the shelf temperature 
setpoint which in turn correlates with the nucleation temperature, on the success of a 
controlled ice nucleation process. Moreover, it was found that all other investigated factors, 
namely the filling height represented by the vial format-independent SV-ratio, the total 
solute concentration, and also the hold time after the nucleation event are key factors for a 
successful CN process. Based on these results and recent literature findings, general 
recommendations for controlled ice nucleation process design were made. However, this 
investigation could only be a piece in the jigsaw puzzle of characterizing the factors and 
variables for a stable controlled ice nucleation process. 
In the future, the need for a broad systematic investigation on the factors influencing the 
controlled ice nucleation process the most is consistently high. Especially formulation 
aspects, as well as the inclusion of critical quality attributes of a drug product, seem 
important. Moreover, it should be taken into account that vacuum-induced surface freezing 
was reported to behave both process-wise and product-wise differently than depressurization 
and most likely also ice fog CN methods. If such a future study is meticulously planned and 
performed, eventually the generation of a predictive mathematical model to gain an 
operational design space seems feasible.  
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VI.1 Abstract 
Freeze-drying is the drying technology of choice for sensitive biological drugs. On the one 
side, it is admired for its suitability for the stabilization of sensitive molecules. On the other 
side, it is a time-consuming production step posing challenges in process development and 
technology transfer. The application of controlled ice nucleation is one elegant approach to 
shorten freeze-drying times significantly and at the same time increasing batch homogeneity. 
However, a reliable 100 % control of the controlled nucleation step in each vial is essential 
considering the impact of the nucleation temperature on product quality attributes. In this 
study, we introduce a camera-supported optical inspection method which utilizes the 
different superficial cake structures seen in controlled and random nucleated lyophilizates. 
Derived from the grayscale analysis the new distinguishing criterion “average edge 
brightness” is introduced. Four different formulations containing Sucrose, Trehalose, and/or 
BSA were freeze-dried with random or controlled nucleation and analyzed with the new 
technology. A proof of concept is provided by the analysis of a similar-to-market lyophilized 
monoclonal antibody formulation freeze-dried with three different freezing protocols 
covering different nucleation profiles. For all investigated formulations and process 
conditions, the clear discrimination of controlled and randomly nucleated vials was possible. 
By this, the technology allowed for reliable, non-invasive, and automatable 100 % 
monitoring of controlled nucleation success after freeze-drying. 
 
Keywords 
Lyophilization; Freeze-drying; Cake structure; Controlled nucleation; Inspection; 
Morphology; Visualization; Protein  
 
Abbreviations 
ANOVA Analysis of variance  
BET  Brunauer–Emmet–Teller krypton gas adsorption 
BSA  Bovine serum albumin 
CI  Confidence interval of the mean 
CN  Controlled ice nucleation 
FD  Freeze-drying 
FMS  Frequency-modulated spectroscopy 
ICH  International conference on harmonization 
IQR  Interquartile range 
M  Mean 
mAb  Monoclonal antibody 
pChamber  Chamber pressure 
PES  Polyethersulfone 
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RN  Random shelf-ramped nucleation 
RM  Residual moisture content 
SD  Standard deviation 
SSA  Specific surface area 
TN  Ice nucleation temperature 
TShelf  Shelf temperature setpoint 
WFI  Water for injection 
VI.2 Introduction 
In the field of biologicals, freeze-drying is still the method of choice to improve long-term 
stability compared to liquid formulations.69,158 By 2018, freeze-dried products represented a 
33 % share of all parenteral protein formulations approved by the European Medicines 
Agency.111 This is an impressive percentage keeping in mind the disadvantages of an 
additional production step resulting in often long processes and complex scale-up 
challenges.41,67,69,113,145 One approach intensively discussed in the freeze-drying community 
to alleviate such downsides is the application of controlled ice nucleation (CN) during 
freezing.40,41,50,53–56 In brief, it refers to the control of the nucleation temperature (TN) of all 
vials and thus control of the degree of supercooling by setting a stimulus to the supercooled 
solutions. Depending on the technology, the most common stimuli types can be (1) the 
introduction of ice seeds by ice fog 41,44–49, (2) the application of rapid pressure changes 
48,50,51 or (3) the application of vacuum to induce local surface freezing 52–54. In general, 
controlled ice nucleation was reported to improve both process times 40,43,50,52,53,55 and batch 
or product quality attributes 40,43,54–59 of the lyophilizates. To our knowledge, first companies 
already started to implement commercial controlled ice nucleation processes into their 
production facilities. By this, the question of nucleation success and how to monitor it raises. 
Geidobler et al. 21 reviewed different published CN methods and found no technology which 
could reliably prove to succeed in 100 % of the vials. Therefore, a full batch control of the 
nucleation success seems essential to overcome this uncertainty for quality assurance and 
regulatory reasons, e.g. if the application of controlled ice nucleation is performed to 
improve reconstitution times or other product quality attributes. Also, reliable discrimination 
of nucleated vs. non-nucleated samples can be used for process validation. The only 
published method for nucleation success control was recently described by Vollrath et al. 
159. They discriminated CN failure vials by the calculated parameter water activity (aw) 
derived from frequency-modulated spectroscopy (FMS). They confirmed the FMS results 
by visual assessment of macroscopic cake appearance and found the FMS method to be 
suitable for the determination of nucleation success. FMS is determining the partial pressure 
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of water in the headspace of the primary container as a surrogate for residual moisture 
content which in turn is highly dependent on the specific surface area of the cake. The latter 
is directly affected by the ice nucleation temperature/ice morphology.18,41,44 Additionally, 
the determined partial pressure values are strongly time-dependent, resulting in a minimum 
equilibration time of days needed before a meaningful measurement can take place.160 That 
is why we alternatively focused on macroscopic differences in the superficial cake structure. 
We developed a new technique that is assessing these structural differences with a camera-
supported optical inspection. It mainly determines differences in grayscale values which are 
dependent on the porosity, granularity, and looseness (density) of the cake. The main 
advantage of this technology would be the potential to be fully implemented in automated 
visual inspection to ensure a 100 % control of the batch after FD. It would allow 
discriminating vials that failed during the controlled ice nucleation step and consequently 
nucleated at a later point in freezing. These vials would resemble randomly nucleated vials. 
The current study examines the feasibility of camera-supported optical inspection for the 
discrimination between random shelf-ramped (RN) and controlled ice nucleated (CN) 
samples. A sample that has not undergone controlled nucleation during a respective freeze-
drying protocol is assumed to be similar to a randomly nucleated sample which is in 
accordance with a report by Vollrath et al. 159. In the first part of this study, we investigated 
the glass-forming excipients Sucrose and Trehalose as placebos and with bovine serum 
albumin added. These formulations were freeze-dried with three different drying protocols, 
i.e. with controlled ice nucleation applied at -5 °C or random shelf-ramped nucleation with 
or without a secondary drying step. The latter was varied to investigate the robustness of the 
method over a broad range of residual moisture contents. In the second part, we studied the 
effect of three different freezing protocols covering random nucleation and controlled ice 
nucleation at -5 °C and -10 °C on a similar-to-market highly concentrated mAb formulation 
containing 120 g/L mAb and 8 % Trehalose. The parameter “average edge brightness” was 
introduced and examined for its feasibility as a distinction criterion under different 
conditions. We hypothesize that on the one hand the visually assessable superficial 
differences between random shelf-ramped and controlled nucleated samples can be assessed 
by a camera-supported inspection system. On the other hand, we anticipate the “average 
edge brightness” to be a reliable distinguishing criterion for all investigated conditions. 
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VI.3 Materials and methods  
VI.3.1 Materials 
Bovine serum albumin (BSA) which contained the heat shock fraction and was protease, 
fatty acid, and essentially globulin free (pH 7, ≥98 %) was purchased from Sigma-Aldrich 
(Steinheim, Germany). A formulation with a monoclonal antibody IgG type 1 (mAb) 
containing 120 g/L mAb, 8 % (w/v) Trehalose, histidine buffer, and polysorbate 80 was on 
stock at LMU and stored at <-65 °C before usage. 
For the placebo and BSA formulations, the following excipients were used: D(+)-Sucrose, 
Extra Pure, SLR was obtained from Fisher Chemical (Leicestershire, UK). D(+)-Trehalose 
dihydrate, 99 %, Acros Organics™ was purchased from Acros Organics BVBA (Geel, 
Belgium). EMPROVE® exp sodium dihydrogen phosphate dihydrate was obtained from 
Merck KGaA (Darmstadt, Germany). Di-sodium hydrogen phosphate dihydrate (≥98.5 %) 
was purchased from Honeywell Fluka™ (Morris Plains, NJ, USA). Acetic acid 99/100 % 
chem. (BP) was obtained from Brenntag GmbH (Essen, Germany). 
For the preparation of buffers and stock solutions, water for injection (WFI; Milli-Q® 
Advantage A10, Merck KGaA, Darmstadt, Germany) was used. For reconstitution of the 
lyophilizates WFI (Purelab Plus, USF Elga, Celle, Germany) was used, too. 
VI.3.2 Preparation of formulations 
50 g/L of BSA were dissolved in the respective placebo formulation in a 25 mM sodium 
phosphate buffer at pH 7.4 (Table VI-1). 
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Table VI-1 Formulations used in the study. 
Formulation mAb 
[g/L] 
BSA 
[g/L] 
Sucrose 
[% (w/v)] 
Trehalose 
dihydrate 
[% (w/v)] 
Methionine 
[% (w/v)] 
Polysorbate 
20 [% (w/v)] 
Sucrose / / 5 / / / 
Sucrose + BSA / 50 5 / / / 
Trehalose / / / 5 / / 
Trehalose + 
BSA 
/ 50 / 5 / / 
mAb 
formulation 
120 / / 8 0.15 0.04 
All placebo and BSA formulations were formulated in a 25 mM sodium phosphate buffer at pH 7.4. The mAb 
formulation was formulated in 20 mM histidine buffer at pH 5.5. 
 
The mAb formulation was stored as a deep-frozen bulk drug substance. An aliquot was 
thawed in a water bath at room temperature and homogenized by gentle swaying. All 
formulations were filtered using a 0.22 µm PES Sartolab® RF vacuum filter unit (Sartorius 
AG, Goettingen, Germany). Subsequently, their concentration was measured with a 
NanoDrop™ 2000 UV photometer (Thermo Scientific, Wilmington, Delaware) at 280 nm 
using an extinction coefficient of ε0.1% = 0.667 g/100 mL
−1 cm−1 and an extinction coefficient 
of ε = 225,000 M−1 cm−1 with a molecular weight of MW = 145.5 kDa for BSA and mAb, 
respectively. 3 mL of each formulation was filled in 10R tubing vials (MGlas AG, 
Muennerstadt, Germany) and semi-stoppered with lyophilization stoppers (FluroTec® 
rubber stopper, West Pharmaceuticals, Eschweiler, Germany).  
VI.3.3 Freeze-drying processes 
All placebo and BSA formulations (Table VI-1) were freeze-dried with three different 
protocols: two with random shelf-ramped nucleation with (RN w SD) or without secondary 
drying (RN w/o SD) and one with controlled ice nucleation at -5 °C shelf temperature 
setpoint (CN) using depressurization technique on a Christ ε2-12D pilot-scale freeze-dryer 
(Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) as 
summarized in Table VI-2. Non-optimized conservative cycles were used. 
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Table VI-2 Overview of the applied freezing and drying protocols for the placebo and BSA formulations. 
FD 
process 
Setpoint Freezing 
Primary 
Drying 
Secondary 
Drying 
       
RN w SD TShelf [°C] 20 5 -50 -20 30 
 Ramp [K/min] - 1 1 1 0.25 
 Hold time [min] 10 60 120 3060 540 
 pChamber [µbar] - - - 90 90 
       
RN w/o SD TShelf [°C] 20 5 -50 -20 - 
 Ramp [K/min] - 1 1 1 - 
 Hold time [min] 10 60 120 3060 - 
 pChamber [µbar] - - - 90 - 
       
CN TShelf [°C] 20 -5 -5 -50 -15 35 
 Ramp [K/min] - 1 - 1 1 0.22 
 Hold time [min] 10 30 60 120 1644 540 
 Stabilization time 
[min] 
- 30* - - - - 
 pChamber [µbar] - 2.7 x 106* - - 90 90 
* Settings for the depressurization ice nucleation technique were as follows: chamber was pressurized to 2.7 
bar ± 0.15 bar absolute pressure with pressurized air and nitrogen with a stabilization time of 30 minutes and 
a subsequent rapid pressure release to introduce controlled nucleation. The stabilization time and pressure 
setpoint were applied after the hold time stated in the same section. 
 
The mAb formulation (Table VI-1) was freeze-dried using three different processes which 
mainly differed in the applied freezing protocol. These protocols comprised random shelf-
ramped nucleation (RN) and controlled ice nucleation at both -5 °C (CN @ -5°C) and -10 
°C (CN @ -10°C) using an ice fog technique on a Christ ε2-6D laboratory-scale freeze-dryer 
(Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) as 
summarized in Table VI-3. Non-optimized cycles were used. 
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Table VI-3 Overview of the applied freezing and drying protocols for the mAb formulation. 
Freeze-drying  
process 
Setpoint Freezing 
Primary 
Drying 
Secondary 
Drying 
       
RN TShelf [°C] 20 5 -50 30 30 
 Ramp [K/min] - 1 1 1 - 
 Hold time [min] 10 60 180 540b 420 
 pChamber [µbar] - - - 90 90 
       
CN @ -5°C TShelf [°C] 20 -5 -5 -50 30 40 
 Ramp [K/min] - 1 - 1 1 1 
 Hold time [min] 10 60 60 180 717c 480 
 pChamber [µbar] - - / a - - 90 90 
       
CN @ -10°C TShelf [°C] 20 -10 -10 -50 30 40 
 Ramp [K/min] - 1 - 1 1 1 
 Hold time [min] 10 60 60 180 457d 480 
 pChamber [µbar] - - / a - - 90 90 
a Settings for the ice fog ice nucleation technique were as follows: chamber pressure was reduced to 15 mbar 
± 10 mbar with a subsequent introduction of ice crystals in the chamber by aeration through the ice condenser 
utilizing the external volume of the LyoCoN (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am 
Harz, Germany). Before the evacuation of the chamber, the designated hold time was held at atmospheric 
pressure.  
b Primary drying endpoint was determined automatically by comparative pressure measurement using a relative 
Δp = 15%.  
c Primary drying endpoint was determined automatically by comparative pressure measurement using a relative 
Δp = 15% and ΔT = 1 °C between the lowest thermocouple and the shelf temperature. 
d Primary drying endpoint was determined automatically by comparative pressure measurement using a relative 
Δp = 15% and ΔT = 8 °C between the lowest thermocouple and the shelf temperature. 
VI.3.4 Karl Fischer titration 
Karl Fischer titration equipped with a headspace module was used to determine residual 
water content after freeze-drying. Due to huge expected differences in residual moisture 
content, sample aliquots between 6 mg and 59 mg were prepared in a glove box filled with 
pressurized air with a relative humidity of less than 10 %, filled into 2R vials and stoppered. 
The samples were then placed in an oven with 100 °C to enable the fast extraction of water. 
The headspace moisture is transported into a coulometric Karl Fischer titrator (Aqua 40.00, 
Elektrochemie Halle, Halle (Saale), Germany). Results are calculated in relative water 
content (w/w). For verification of equipment performance, three aliquots of Apura® water 
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standard oven 1 % by Merck KGaA (Darmstadt, Germany) were measured within a 
sequence. Results are given as mean ± standard deviation (n=3). 
VI.3.5 Brunauer-Emmet-Teller krypton gas adsorption 
The specific surface area of dried samples was determined using Brunauer–Emmet–Teller 
(BET) krypton gas adsorption in a liquid nitrogen bath at 77.3 K (Autosorb 1; 
Quantachrome, Odelzhausen, Germany). Approximately 100 to 400 mg of a sample was 
gently crushed with a spatula and weighed into glass tubes. Prior to measurement, an 
outgassing step was performed for at least 6 h at room temperature. An 11-point gas 
adsorption curve was measured, covering a p/p0 ratio of approximately 0.05– 0.30. Data 
evaluation was performed according to the multi-point BET method fit of the Autosorb 1 
software. Results are given as mean ± standard deviation (n=3). 
VI.3.6 Reconstitution of lyophilizates 
The lyophilized cakes were reconstituted by the addition of WFI. The WFI volume for each 
formulation was calculated to match the volume of the water removed during freeze-drying. 
Reconstitution time was determined by recording the time between adding the respective 
formulation-specific volume of water for injection and obtaining a clear solution without 
visible matter. This observation was performed by manual visual inspection. Reconstitution 
was performed applying gentle swirling for 5 s directly after the addition of water and then 
letting the vial stand without further swirling. 
VI.3.7 Camera-supported optical inspection 
The vials were placed centrally on top of a laboratory manual camera build with a centric 
white ring light above it as illustrated in Figure VI-1 (Seidenader Maschinenbau GmbH, 
Markt Schwaben, Germany). The camera in use was a monochromic 1.2 megapixel TXG12-
type (Baumer Holding AG, Frauenfeld, Switzerland). 
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Figure VI-1 Schematic illustration of the laboratory camera setup with the vial containing the lyophilizate 
placed centrally above a camera equipped with a ring light centric above the vial.  
The ring light illuminated the lyophilized cake from above so that the camera was taking an 
image of the scattered light. Dependent on the looseness (density), porosity, and granularity 
of the cake a grayscale image of the bottom cake structure was taken (Figure VI-2 and Figure 
VI-3A).  
 
A 
 
 
B 
Figure VI-2 Raw example pictures of A the mAb formulation dried with protocol RN from Table VI-3 and 
B the same formulation processed with protocol CN @ -5°C from Table VI-3. 
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The underlying algorithm is described briefly in the following: the differentiation was 
realized by the comparison of grayscale-associated parameters. Cracks within a cake would 
have caused artificially high grayscale values. In order to exclude these cracks from further 
investigation, an average grayscale value of the image was calculated. Larger areas of the 
picture exceeding a certain average grayscale range threshold were excluded. The resulting 
image is shown in Figure VI-3B and represented the mask image.  
 
A 
 
B 
 
C 
 
D 
Figure VI-3 Image processing by the algorithm at the example of Sucrose+BSA formulation dried with 
protocol CN from Table VI-2. A raw image, B mask image representing areas exceeding the average 
grayscale range threshold C first derivative of the raw picture revealing edges D difference image of the first 
derivative (C) and the mask image (B) for the determination of the “average edge brightness”. 
 
The first derivative of the raw image was calculated to amplify light-dark-transitions 
revealing edges (Figure VI-3C). These are small-sized pixel areas with strong grayscale 
differences inside the investigated pixels. Eventually, the difference image of the first 
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derivative of the raw picture (Figure VI-3C) and the mask image (Figure VI-3B) was 
generated. By that, the absolute grayscale value became negligible. The resulting difference 
image was used for calculation of the “average edge brightness” which was the main 
distinguishing criterion based on grayscale and edges (Figure VI-3D).The technical set-up 
and algorithm can be implemented on all machine platforms of the provider and is therefore 
integrable in an automated inspection station.  
VI.3.8 Statistical analysis 
For statistical analysis and regression analysis, Minitab 19 Statistical Software (Minitab, 
LLC., State College, PA, USA) and OriginPro 2017 (OriginLab Corporation, Northampton, 
MA, USA) were used. A one-way ANOVA with Tukey’s method was used for statistical 
testing at a significance level of α = 5% or α = 0.1%. The normal distribution of the data sets 
was tested using the Anderson-Darling test. Due to the small sample size for specific surface 
area and reconstitution time (n=3), all tests for normal distribution (Anderson-Darling, 
Ryan-Joiner, Kolmogorov-Smirnov) of the samples resulted in a normally distributed 
population. This was in agreement with the authors’ expectations based on the nature of 
investigated data (specific surface area, reconstitution times). Hence, a normal distribution 
of these parameters was assumed.  
  
 
 109 
VI.4 Results 
VI.4.1 Residual moisture content and specific surface area 
The results for residual moisture (RM) and specific surface area (SSA) analysis are presented 
in Figure VI-4. Due to the different freeze-drying protocols used (Table VI-2), a range of 
lyophilizates with different RM was produced. For the Sucrose placebo formulations (Figure 
VI-4A) residual moisture values between 2.2 % ± 0.1 % and 1.6 % ± 0.2 % for CN and RN 
w SD, respectively, were obtained. As expected, the application of controlled nucleation 
reduced the specific surface area. The drying protocol with random nucleation and without 
a secondary drying step (Table VI-2, RN w/o SD) resulted in partially liquid collapsed 
samples for Sucrose placebos which have not been used for further analysis.  
 
Figure VI-4 Residual moisture content (bars) and specific surface area (symbols) results for the different 
formulations. A Sucrose and Sucrose+BSA, B Trehalose and Trehalose+BSA, and C IgG1 mAb formulation. 
Values shown represent the mean value (n = 3) ± standard deviation. 
 
In contrast, Sucrose + BSA samples resulted in cake-like structures for all applied freeze-
drying protocols revealing moisture contents in a range of 1.2 % ± 0.1 %, 0.3 % ± 0.1 %, 
and 9.6 % ± 1.2 % for CN, RN w SD and RN w/o SD, respectively. The corresponding 
specific surface areas indicate a microscopic collapse for the random shelf-ramped nucleated 
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samples which did not undergo secondary drying by a 40 % reduced SSA of 0.56 m²/g ± 
0.05 m²/g. In contrast to that, CN samples revealed an even smaller specific surface area of 
0.33 m²/g ± 0.00 m²/g which was determined by the freezing step and by elevated residual 
moisture.  
Similar observations were made for Trehalose placebo and Trehalose + BSA samples 
(Figure VI-4B). The former covered a range of residual moisture contents from 2.4 % ± 0.1 
%, 0.9 % ± 0.1 % and 8.9 % ± 0.3 % for CN, RN w SD and RN w/o SD, respectively. A 
smaller extent of microscopic collapse by a 29 % reduction in SSA was observed for the RN 
w/o SD samples compared to the corresponding samples with secondary drying (RN w SD). 
Controlled nucleated samples again showed a strongly decreased specific surface area of 
0.58 m²/g ± 0.03 m²/g in comparison to 1.58 m²/g ± 0.16 m²/g obtained for RN w SD solids. 
Trehalose + BSA lyophilizates revealed lower residual moisture contents and specific 
surface areas compared to placebo except for the moisture content of RN w/o SD. The BSA 
containing Trehalose samples showed moisture levels of 1.1 % ± 0.1 %, 0.3 % ± 0.1 % and 
11.0 % ± 1.4 % for CN, RN w SD and RN w/o SD, respectively. Overall, as mentioned, 
specific surface areas were found to be smaller with 0.35 m²/g ± 0.01 m²/g for CN, 1.02 m²/g 
± 0.11 m²/g, and 0.65 m²/g ± 0.04 m²/g for RN w SD and RN w/o SD, respectively, than for 
the pure placebo. The investigated IgG1 mAb formulation underwent three different freezing 
procedures whereas drying conditions were kept similar (Table VI-3). Samples were found 
to be dry with only slightly higher moisture levels of 0.4 % (CN @ -5°C) and 0.3 % (CN @ 
-10°C) compared to 0.2 % residual moisture within random shelf-ramped nucleated samples 
(RN). However, specific surface areas differed statistically significant as indicated by non-
overlapping 95 % confidence intervals of the mean (Figure VI-5). 
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Figure VI-5 Specific surface area of the mAb formulation dependent on the nucleation temperature. Symbols 
represent the mean value with its 95 % confidence interval.  
 
VI.4.2 Average edge brightness 
The “average edge brightness” values derived from the raw image analysis for the different 
formulations and freeze-drying protocols are presented in Figure VI-6.  
Sucrose placebos revealed a significant difference in the determined “average edge 
brightness” of 10.48 ± 0.15 (95 % CI = 10.42, 10.53) compared to 41.15 ± 3.20 (95 % CI = 
39.95, 42.34) for RN and CN, respectively (Figure VI-6A).  
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Figure VI-6 “Average edge brightness” depending on the different formulations and freeze-drying protocols. 
A Sucrose and Sucrose+BSA, B Trehalose and Trehalose+BSA, and C IgG1 mAb formulation. The red 
horizontal line represents the individually set distinction limit of 20 and 13.9 for A/B and C, respectively. 
Individual values of 30 different vials were recorded per data set. 
 
The same clear discrimination between random shelf-ramped nucleated samples and 
controlled ice nucleated samples was found for Sucrose-based BSA samples. These 
exhibited values of 11.09 ± 0.91 (95 % CI = 10.75, 11.43) for RN w SD-samples and 37.19 
± 2.43 (95 % CI = 36.28, 38.09) for samples which underwent the CN-protocol. Even high 
residual moisture content within the Sucrose + BSA-matrix (RN w/o SD) only slightly 
increased the “average edge brightness” to 12.13 ± 1.40 (95 % CI = 11.61, 12.65) compared 
to identical samples which underwent a desorption step. Moreover, the slight yellow cake 
color introduced by the addition of BSA did not decrease the resolution of the discrimination 
parameter.  
Similar results were found for both Trehalose lyophilizates with and without BSA (Figure 
VI-6B). On the one hand, absolute differences in Trehalose placebo decreased between RN 
without SD (M = 12.35, SD = 1.25, 95 % CI = 11.75, 12.95) and with a secondary drying 
step (M = 9.51, SD = 0.95, 95 % CI = 9.16, 9.87) compared to CN samples (M = 27.70, SD 
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= 2.91, 95 % CI = 26.62, 28.79). On the other hand, no such reduction was found for 
Trehalose formulations with BSA neither for RN without SD (M = 15.82, SD = 1.71, 95 % 
CI = 15.18, 16.46) or for RN with secondary drying (M = 14.02, SD = 1.28, 95 % CI = 13.54, 
14.50) nor for CN samples (M = 40.08, SD = 2.85, 95 % CI = 39.01, 41.14).  
As a proof of concept, the newly introduced discrimination parameter of “average edge 
brightness” was investigated for a similar-to-market highly concentrated IgG1 formulation 
nucleated with three different freezing protocols (Figure VI-6C). Values obtained for 
random shelf-ramped nucleated samples (RN) of 11.57 ± 0.69 (95 % CI = 11.32, 11.83) were 
in between the “average edge brightness” obtained for Trehalose placebos (9.51 ± 0.95) and 
Trehalose + BSA (14.02 ± 1.28). Interestingly, the “average edge brightness” of 27.16 ± 
1.79 (95 % CI = 26.49, 27.83) for CN @ -5°C was found to be essentially the same as for 
the Trehalose placebo formulation with CN (27.70 ± 2.91) but not for the Trehalose + BSA 
with CN (40.08 ± 2.85). However, clear discrimination between RN and CN @ -5°C samples 
was possible. For controlled ice nucleation at -10 °C lower values of 16.30 ± 1.23 (95 % CI 
= 15.84, 16.75) were found; slowly approximating to the value of RN. Yet, the mean values 
of the two populations, RN and CN @ -10°C, were still different on a significance level of 
p < .001 as shown in Figure VI-7A and analyzed by a one-way ANOVA. Moreover, a clear 
distinction between the two populations can be seen in the box-plot (Figure VI-7B) showing 
the measure of location and statistical dispersion for the different freezing protocols. Only 
single outliers of the RN sample set approximated close to the distinction limit. Overall, the 
method was still capable to discriminate between RN and CN @ -10°C for all samples. 
 
Figure VI-7 “Average edge brightness” of the mAb formulation dependent on the nucleation temperature. A 
99.9 % confidence intervals of the mean. B Box-plot of differently frozen populations showing the measure of 
location and statistical dispersion. The red horizontal line represents the individually set distinction limit of 
13.9.  
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VI.4.3 Reconstitution time 
Controlled nucleation was reported to reduce reconstitution times in protein formulations 
48,56,57,161, especially in highly concentrated protein formulations 57,161. Figure VI-8 shows 
the 95 % confidence intervals of the mean reconstitution times for the different freezing 
protocols used for the highly concentrated similar-to-market formulation. Surprisingly, no 
positive effect on reconstitution behavior was found. We, therefore, suggest that this is 
highly dependent on the chosen formulation (mAb, excipients) and applied process 
conditions. 
 
Figure VI-8 Reconstitution time of the mAb formulation dependent on the nucleation temperature. Symbols 
represent the mean value with its 95 % confidence interval. 
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VI.5 Discussion 
VI.5.1 The feasibility of optical camera inspection for determination of 
nucleation success 
Controlled ice nucleation has been intensively discussed in the literature for its potential 
advantages over random shelf-ramped nucleation in terms of process improvements 
40,43,50,52,53,55 and critical product quality attributes 40,43,54–59. However, especially due to 
potentially more aggressive cycles that can be applied with controlled ice nucleation, 
assurance of 100 % nucleation success becomes essential. For example, Goshima et al. 162 
showed that the design space of a product is directly affected by the ice morphology with 
larger pores significantly enlarging the design space. The design space as part of quality by 
design is expected by regulatory agencies based on ICH Q8(R2) and was investigated for its 
implementation in freeze-drying process development.163–166 The application of controlled 
ice nucleation can be seen as one control strategy to fulfill regulatory expectations. However, 
its implementation requires a reliable assessment of the nucleation success batch by batch 
for validation, scale-up, and quality assurance purposes. Hence, the need for an easy-
implementable and non-invasive method for 100 % controlled ice nucleation success 
assessment is high. 
The only published method for nucleation success control was recently described by Vollrath 
et al. 159. They discriminated CN failure vials by the application of frequency-modulated 
spectroscopy (FMS). FMS is determining the partial pressure of water in the headspace of 
the primary container as a surrogate for residual moisture content. The latter is highly 
dependent on the specific surface area which is directly affected by the ice nucleation 
temperature/ice morphology.18,41,44 Partial pressure values are strongly time-dependent and, 
therefore, several days of holding or intermediate storage time would be needed after a batch 
has been unloaded from the freeze-dryer.160 Our alternative approach, the camera-supported 
optical inspection, is based on the assessment of macroscopic differences in the cake surface 
structure. It was noticed by several authors that controlled nucleated lyophilization cakes 
reveal a more porous, loose, i.e. less dense, and more or less granular structure with a higher 
rate of cracks compared to random shelf-ramped lyophilizates.159,167 Figure VI-6 
demonstrates that the “average edge brightness” derived from the optical inspection was a 
good and reliable distinguishing criterion for discrimination between RN and CN. It was 
shown that a clear and reproducible differentiation in different pharmaceutically relevant 
amorphous excipient systems was feasible. In Sucrose formulations with or without bovine 
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serum albumin the best resolution, i.e. the greatest distance of single values to the distinction 
limit, between randomly and controlled nucleated vials was found (Figure VI-6A). For 
Trehalose-based formulations resolution decreased slightly, but yet differently treated 
populations were very well distinguishable (Figure VI-6B). Based on these results, the 
authors conclude that the method was neither affected by the change in composition (type of 
excipient, total solid content, introduction of polymer-like BSA) nor by extremely different 
residual moisture content (Figure VI-4A+B). In fact, the “average edge brightness” was 
almost unaffected by residual moisture differences, even though BET measurements 
indicated differences in microscopic structure. For example, for BSA-containing Trehalose 
lyophilizates with and without secondary drying, residual moisture contents of 0.3 % and 
11.0 %, respectively, were found. Corresponding “average edge brightness” values were 
14.02 ± 1.28 (w SD) and 15.82 ± 1.71 (w/o SD), although specific surface areas were found 
to be apparently different with 1.02 m²/g ± 0.11 m²/g and 0.65 m²/g ± 0.04 m²/g for RN w 
SD and RN w/o SD, respectively. Although both microscopic collapse due to high RM 
content and application of CN led to a significant decrease in SSA, “average edge 
brightness” was still capable of distinguishing between randomly and controlled nucleated 
samples. Moreover, it seems obvious that regularly found moisture differences between 
center- and edge-vials within one freeze-drying run would not affect the resolution of the 
newly proposed method. 
The proof of concept of our approach was provided by the investigation of a similar-to-
market formulation with a highly concentrated IgG1 in a Trehalose-based formulation. In 
contrast to the placebo + BSA formulations, two different controlled ice nucleation protocols 
were applied and compared to a random shelf-ramped freeze-drying cycle (Table VI-3). 
Figure VI-5 shows that the different species are statistically significantly different 
concerning the specific surface area. These SSA values translated into a pronounced 
macroscopic difference between RN and CN @ -5°C samples as shown exemplarily in 
Figure VI-2. Consequently, the clear discrimination of these two populations based on 
“average edge brightness” was possible (Figure VI-6C, Figure VI-7). A distinction between 
samples produced by random nucleation and controlled nucleation at -10 °C was still feasible 
(Figure VI-6C). However, a few individual outliers of the RN population appeared to result 
in quite similar “average edge brightness” values as obtained for CN @ -10°C (Figure 
VI-7B). This is because the morphology and specific surface area of the cake are primarily 
determined by the nucleation temperature.18,50 Experimentally obtained nucleation 
temperatures for random shelf-ramped nucleation were reported by Konstantinidis et al. 50 
 
 117 
to be in the range of -7.2 °C to -16.6 °C for a 5 % Sucrose formulation in a laboratory setup. 
The freezing behavior of Sucrose and Trehalose is presumably the same, wherefore RN 
samples were probably stochastically nucleating within the same temperature range. This 
resulted in a potential overlap with samples that were controlled nucleated at -10 °C. 
However, all different mAb formulation samples were still reliably distinguished.  
VI.5.2 Average edge brightness as a surrogate with reservations for 
specific surface area  
The specific surface area determined by BET measurement is a sensitive measure for 
freezing- 41,44 or drying-induced 168 changes. However, its destructive and time-consuming 
character are typical drawbacks. In contrast, a non-invasive, rapid surrogate for routine 
measurements could be attractive. The newly introduced “average edge brightness” showed 
the potential to distinguish between samples nucleated at different nucleation temperatures 
corresponding to different SSA values. A simple linear regression model revealed already a 
good negative correlation as shown in Figure VI-9. Such a model could be used for routine 
verification during production instead of SSA analysis. 
However, the prognostic R² is rather low and needs to be improved to predict specific surface 
area values accurately for a known formulation. This could be particularly of interest when 
platform formulations are used. In the course of freeze-drying process development, the 
collection of a sufficiently big data set for a formulation-specific mathematical model is 
imaginable which could allow for “designing” the drying characteristics of a new product 
based on porosity indirectly assessed by rapid camera inspection. Consequently, the 
“average edge brightness” could be of value as a surrogate with reservations for SSA in 
future development processes. 
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Figure VI-9 Linear regression model with “average edge brightness” over the specific surface area containing 
data of the mAb formulation processed at three different freezing protocols (Table VI-3). 
VI.5.3 Limitations 
Based on the results obtained for the mAb formulation (Figure VI-6C, Figure VI-7B) the 
discrimination of CN samples nucleated at low nucleation temperatures (i.e. ≤ -10 °C) could 
be limiting. However, the resolution may be improved with lyophilizates produced in a Class 
100 cleanroom environment. This assumption is based on theoretical considerations and 
practical observations described in the literature for random shelf-ramped freezing. The 
cleaner the environment, the lesser potential airborne nucleation sites are present, leading to 
a higher degree of supercooling and thus, huger differences in nucleation temperatures 
compared to those obtained in controlled ice nucleation.18,41,44,58,169 Rambhatla et al. 
estimated that solutions in the manufacturing scale would typically experience 
approximately 20 °C supercooling 41 compared to ~13 °C – 14 °C supercooling observed by 
Searles et al. 18 and Fang et al. 58 in a laboratory environment. Additionally, the applied 
algorithm for raw image processing was kept rather simple. By changes in thresholds or 
further addition of filters to the image processing procedure, an optimization of the 
resolution is feasible as well. 
 
 119 
VI.6 Conclusion 
We describe a new method to discriminate in freeze-drying with controlled ice nucleation 
between vials that nucleate at controlled nucleation conditions and others that fail and 
nucleate at a later stage in freezing, using camera-supported optical inspection. The 
parameter “average edge brightness” which can be easily derived from a raw image taken 
from the bottom of the vial with a simple raw image processing is introduced. It is 
successfully applied to Sucrose- and Trehalose-based placebo and BSA formulations 
resulting in a clear distinction between random shelf-ramped (i.e. vials that failed CN) and 
controlled nucleated samples. A proof of concept is provided by applying the technology to 
a similar-to-market high concentrated IgG1 mAb formulation with Trehalose which 
underwent three different freezing protocols, i.e. random nucleation and controlled ice 
nucleation at -5 °C and -10 °C. The sample populations were found to be statistically 
significantly different with a significance level of p < .001 with respect to the “average edge 
brightness”. By this, the technology allows for reliable, non-invasive, and potentially 
automatable 100 % monitoring of controlled nucleation success after freeze-drying.  
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Chapter VII Final summary and conclusion of the thesis 
The primary aim of the first part of this thesis was to study the feasibility and applicability 
of microwave-assisted freeze-drying to monoclonal antibody formulations in vials. 
Chapter I gave a general introduction to the basic principles of conventional freeze-drying 
and a brief overview of emerging technologies like MFD with their reported advantages and 
associated challenges. With this background, I investigated in Chapter II the applicability 
of MFD to established excipients used in conventional freeze-drying with a low 
concentration antibody formulation. The excipients studied comprised sucrose, trehalose, a 
4:1 mannitol:sucrose-mixture, a sucrose formulation with only 1 % (w/v) sucrose content, a 
1:1 sucrose:HP-β-CD-mixture as well as an ionic stabilizer system with arginine phosphate. 
I found that microwave-assisted freeze-drying (1) was able to shorten the drying process by 
more than 75 % compared to a conservative CFD cycle and that (2) it could be successfully 
applied for the drying of these formulations. However, higher variances in solid state 
analysis of the samples processed with MFD were found indicating an inferior drying and 
batch homogeneity. Moreover, information on product quality over storage was still lacking. 
For this reason, I studied in Chapter III the storage stability of four different formulations 
with 5 g/L or 50 g/L mAb concentration for six months. Also, I introduced a new generator 
set up to investigate its effect on batch homogeneity. Besides the significant time savings in 
MFD; I was able to elucidate comparable stability profiles for the different antibody 
formulations composed of classical lyophilization excipients like sucrose, trehalose and, 
selected due to findings from Chapter II, arginine phosphate. Even with the extended 
analytical toolbox applied and accelerated stress conditions of 40 °C for 24 weeks, no 
differences in product quality and stability were found between CFD and MFD. Yet again, 
I found indications for an increased batch heterogeneity within MFD batches produced with 
the indirect magnetron generator setup introduced in Chapter II. Especially with respect to 
residual moisture content which is considered one critical quality attribute of lyophilizates 
the first setup appeared less favorable. In contrast, the data of the product batch produced 
with the modern semiconductor solid-state microwave generator (Chapter III) indicated a 
batch homogeneity comparable to the conventionally freeze-dried samples.  
However, future investigations should systematically study the potential and limitations of 
modern generator setups as well as new machinery concepts complying with the 
manufacturing requirements of (sterile) pharmaceutical dosage forms. Besides, the 
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evaluation of critical product quality attributes focusing on chemical changes within a 
protein drug and investigating batch homogeneity analysis could be of particular interest.  
 
In the second part of this thesis, the focus was on unresolved issues of controlled ice 
nucleation like process design, comparability of mechanistically different techniques, and 
non-invasive monitoring of the nucleation success.  
The first two commercially available CN techniques, ice fog and depressurization, were 
compared for the similarity of process performance and critical product quality attributes in 
a case study in Chapter IV. I found that regarding nucleation behavior and resulting process 
length both techniques are well comparable. Moreover, I was able to show that the resulting 
products were practically identical in all three pharmaceutically relevant model formulations 
(sucrose-, trehalose, mannitol-sucrose-based) with respect to solid state properties and in 
protein-related analyses. Therefore, I concluded that the control of ice nucleation as such is 
more relevant than the applied mechanism concerning depressurization and ice fog. 
However, formulation aspects (e.g. mAb and excipient concentration) and different process 
conditions (e.g. different TN or CN protocols) were out of the scope of this study but could 
be of interest for future investigations. 
To deepen the process understanding of different factors on the success of controlled ice 
nucleation, I performed freezing studies in Chapter V taking formulation aspects like solid 
content or filling volume as well as process aspects like shelf temperature or post-CN hold 
time into consideration. A regression model was generated to elucidate the mutual interplay 
of these factors. I demonstrated that in particular, the shelf temperature setpoint for pre-CN 
equilibration and subsequent initiation of the nucleation event is key for a desirable 
nucleation result. Based on the literature and my findings, I made general recommendations 
for the controlled ice nucleation process design (section V.3.4). Still, extensive systematic 
investigations on a good nucleation practice are strongly needed in the future.  
In order to be able to control the nucleation success of a full freeze-dried batch, I developed 
a new camera-supported optical inspection method to particularly detect the vials that failed 
to nucleate during CN. In Chapter VI, I introduced the distinction parameter “average edge 
brightness” which was successfully applied to sucrose- and trehalose-based placebos and 
BSA formulations processed with different freezing protocols and with different residual 
moisture contents. With a high concentration IgG1 mAb formulation freeze-dried with 
different protocols, I demonstrated the proof of concept of this new non-invasive and non-
destructive method with an extremely significant difference of p < .001 for the two sample 
 
 123 
populations with respect to the introduced parameter “average edge brightness”. By this, I 
described a new simple method to reliably perform a 100 % control of controlled ice 
nucleation success after freeze-drying. 
 
Ultimately, this work contains various significant findings in the field of pharmaceutical 
freeze-drying of biologicals. I was able to show the potential of microwave-assisted freeze-
drying for the optimization of freeze-drying in terms of process time while maintaining 
overall product quality. However, also the pitfalls and limitations of the technology as well 
as of the currently available prototype are discussed.  
In the field of controlled ice nucleation, several benefits related to the application of 
controlled ice nucleation have been reported before, so that my findings should rather 
support process scientists in the data-driven implementation of CN. I demonstrated the 
interchangeability of CN techniques depressurization and ice fog. Additionally, I 
systematically investigated the effects of different formulation and CN process parameters 
on the success of controlled nucleation leading to general recommendations for process 
design. Furthermore, I developed a new simple method using camera-supported optical 
inspection for the 100 % control of nucleation success to overcome disadvantages of current 
headspace-based methods which often need long equilibration times to deliver reliable and 
reproducible results.  
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